[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2374
1. Razaq M, Godkar D, Mankan N, Sridhar S, Hussain S, Ohri A: Cat scratch disease mimicking Richter's Syndrome in a patient with chronic lymphocytic leukemia. Leuk Lymphoma; 2005 Mar;46(3):443-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It occurs as a result of transformation of chronic lymphocytic leukemia (CLL) or low grade lymphoma into highly aggressive lymphoma.
  • Initial suspicion of Richter's Syndrome proved wrong when lymph node biopsy did not reveal evidence of high grade lymphoma.


2. Slater DN: The new World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas: a practical marriage of two giants. Br J Dermatol; 2005 Nov;153(5):874-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In particular, it provides a useful distinction between indolent and more aggressive types of primary cutaneous lymphoma and provides practical advice on preferred management and treatment regimens.
  • In cutaneous T-cell lymphomas, these include folliculotropic mycosis fungoides, defining features of Sézary syndrome, primary cutaneous CD30+ lymphoproliferative disorders (primary cutaneous anaplastic large cell lymphoma, lymphomatoid papulosis and borderline lesions) and subcutaneous panniculitis-like T-cell lymphoma.
  • Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma, primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma and cutaneous gamma/delta T-cell lymphoma are allocated provisional entry status and thereby afford better definitions for some cases of currently unspecified primary cutaneous peripheral T-cell lymphoma.
  • In cutaneous B-cell lymphomas, diseases which have found new consensus agreement include primary cutaneous marginal zone B-cell lymphoma, primary cutaneous follicular centre lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type and primary cutaneous diffuse large B-cell lymphoma, other.
  • CD4+/CD56+ haematodermic neoplasm (early plasmacytoid dendritic cell leukaemia/lymphoma) now appears as a precursor haematological neoplasm and replaces the previous terminology of blastic NK-cell lymphoma.
  • The new classification raises interesting new problems and questions about primary cutaneous lymphoma and some of these are discussed in this article.
  • It is, however, a splendid signpost indicating the direction in which research in cutaneous lymphoma needs to go.
  • [MeSH-major] Lymphoma / classification. Skin Neoplasms / classification
  • [MeSH-minor] Humans. Killer Cells, Natural. Lymphoma, B-Cell / classification. Lymphoma, T-Cell, Cutaneous / classification. Mycosis Fungoides / classification. Sezary Syndrome / classification. World Health Organization

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16225594.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 23
  •  go-up   go-down


3. Dunleavy K, Hakim F, Kim HK, Janik JE, Grant N, Nakayama T, White T, Wright G, Kwak L, Gress R, Tosato G, Wilson WH: B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood; 2005 Aug 1;106(3):795-802
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Late-onset neutropenia (LON) was investigated in 130 patients with untreated aggressive B-cell lymphoma receiving DA-EPOCH (dose-adjusted etoposide, prednisone, Oncovin [vincristine], cyclophosphamide, and hydroxydaunorubicin) chemotherapy with or without rituximab.
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemokine CXCL12. Drug Evaluation. Female. Humans. Kinetics. Lymphoma, B-Cell / complications. Lymphoma, B-Cell / drug therapy. Lymphopoiesis. Male. Middle Aged. Neutropenia / chemically induced. Neutropenia / etiology. Regeneration. Retrospective Studies. Rituximab

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1851-7 [10561225.001]
  • [Cites] Immunity. 1999 Apr;10(4):463-71 [10229189.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5028-37 [11431337.001]
  • [Cites] Immunity. 2001 Aug;15(2):323-34 [11520466.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2685-93 [11929754.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2703-11 [11929756.001]
  • [Cites] Nat Immunol. 2002 Jul;3(7):687-94 [12068293.001]
  • [Cites] Exp Hematol. 2002 Sep;30(9):973-81 [12225788.001]
  • [Cites] J Clin Invest. 2003 Jan;111(2):187-96 [12531874.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4653-9 [12609827.001]
  • [Cites] Br J Haematol. 2003 Jun;121(6):913-8 [12786803.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2691-4; discussion 2691-4 [12826650.001]
  • [Cites] Immunity. 2003 Oct;19(4):583-93 [14563322.001]
  • [Cites] J Leukoc Biol. 2003 Nov;74(5):880-8 [12960279.001]
  • [Cites] Bone Marrow Transplant. 2004 May;33(9):921-3 [15034544.001]
  • [Cites] Immunity. 2004 Jun;20(6):707-18 [15189736.001]
  • [Cites] Blood. 2004 Jul 15;104(2):565-71 [15054039.001]
  • [Cites] Nat Med. 2004 Aug;10(8):858-64 [15235597.001]
  • [Cites] J Immunol. 1980 Oct;125(4):1678-85 [6157744.001]
  • [Cites] J Exp Med. 1981 Sep 1;154(3):737-49 [7024458.001]
  • [Cites] Eur J Immunol. 1986 Aug;16(8):881-7 [3091375.001]
  • [Cites] Blood. 1994 Jan 15;83(2):435-45 [7506951.001]
  • [Cites] Immunol Today. 1994 Sep;15(9):450-4 [7524522.001]
  • [Cites] J Clin Oncol. 1997 Oct;15(10):3266-74 [9336364.001]
  • [Cites] Blood. 1997 Nov 1;90(9):3789-98 [9345067.001]
  • [Cites] J Immunol. 1998 Feb 1;160(3):1522-31 [9570576.001]
  • [Cites] Nature. 1998 Jun 11;393(6685):595-9 [9634238.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3135-43 [10963642.001]
  • (PMID = 15718416.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 4F4X42SYQ6 / Rituximab
  • [Other-IDs] NLM/ PMC1895166
  •  go-up   go-down


Advertisement
4. Linch DC, Yung L, Smith P, Maclennan K, Jack A, Hancock B, Cunningham D, Hoskin P, Qian W, Holte H, Boesen AM, Grigg A, Browett P, Trneny M: Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL. Br J Haematol; 2010 Apr;149(2):237-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL.
  • This trial involved 457 patients and sought to assess the value of early intensification with autologous transplantation in patients with poor prognosis histologically aggressive non-Hodgkin lymphoma (NHL) showing a response to initial CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Lymphoma, Large B-Cell, Diffuse / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20201949.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; BEAM regimen; VAP-cyclo protocol
  •  go-up   go-down


5. Weng Y, Gao ZF, Liu K, Zhang WJ, Ke XY, Li M: [Factors affecting the prognosis of diffuse large B-cell lymphoma in Chinese]. Zhonghua Nei Ke Za Zhi; 2005 Sep;44(9):681-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Factors affecting the prognosis of diffuse large B-cell lymphoma in Chinese].
  • OBJECTIVE: To study the correlation between clinical prognosis and clinicopathologic features, origin and cell proliferous index of diffuse large B-cell lymphoma (DLBCL) in China.
  • It is highly aggressive tumor.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16202261.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


6. Liu JK, Sayama C, Chin SS, Couldwell WT: Extranodal NK/T-cell lymphoma presenting as a pituitary mass. Case report and review of the literature. J Neurosurg; 2007 Sep;107(3):660-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal NK/T-cell lymphoma presenting as a pituitary mass. Case report and review of the literature.
  • Extranodal NK/T-cell lymphomas are uncommon neoplasms that are highly aggressive and show a strong association with Epstein-Barr virus.
  • The authors report a case of NK/T-cell lymphoma of the pituitary gland and review 17 cases of PPL from the literature.
  • Patients who had systemic lymphoma with secondary involvement of the pituitary gland were excluded.
  • Thirteen patients (72%) had B-cell lymphoma, four (22%) had T-cell lymphoma, and one (6%) had NK/T-cell lymphoma.
  • The pathological entity of NK/T-cell lymphoma is distinct, and its course is very aggressive with a poor prognosis.
  • [MeSH-major] Lymphoma, T-Cell / pathology. Pituitary Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17886569.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 31
  •  go-up   go-down


7. Yasunaga J, Matsuoka M: [HTLV-I and leukemogenesis]. Uirusu; 2006 Dec;56(2):241-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ATL is a highly aggressive neoplastic disease of CD4 positive T lymphocyte, which is featured by the pleomorphic tumor cells with hypersegmented nuclei, called " flower cell".
  • [MeSH-major] Human T-lymphotropic virus 1. Leukemia-Lymphoma, Adult T-Cell / virology

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17446673.001).
  • [ISSN] 0042-6857
  • [Journal-full-title] Uirusu
  • [ISO-abbreviation] Uirusu
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Basic-Leucine Zipper Transcription Factors; 0 / Gene Products, tax; 0 / HBZ protein, human T-cell leukemia virus type I; 0 / Viral Proteins
  • [Number-of-references] 73
  •  go-up   go-down


8. Freedman AS: Biology and management of histologic transformation of indolent lymphoma. Hematology Am Soc Hematol Educ Program; 2005;:314-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biology and management of histologic transformation of indolent lymphoma.
  • The evolution of indolent lymphomas to aggressive histologies, known as histologic transformation (HT), is a frequent occurrence for all subtypes of low grade B cell lymphoproliferative disorders.
  • The risk of developing HT is approximately 3% per year for patients with indolent lymphoma.
  • Recent studies suggest that the development of HT is very complex with the acquisition of multiple cytogenetic abnormalities in the low-grade lymphoma cells prior to HT.
  • The use of radioimmunotherapy and new agents targeting specific lesions or aberrant pathways may impact on the management of these aggressive diseases.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16304397.001).
  • [ISSN] 1520-4383
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Laatiri MA, Elloumi M, Ali ZB, Ben Othmen T, Msadek F, Toumi N, Bouaouina N, Daoud J, Maalej M, Ghannem H, Meddeb B: [Tunisian experience in the treatment of aggressive non Hodgkin's lymphoma in adults: about 337 patients]. Bull Cancer; 2010 Apr;97(4):409-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tunisian experience in the treatment of aggressive non Hodgkin's lymphoma in adults: about 337 patients].
  • From January 1997 to December 2005, 337 patients with aggressive non Hodgkin's lymphoma were treated with one of the two successive multicentric non randomized protocols established in Tunisia.
  • Most patients had diffuse large cell lymphoma with B phenotype in 86% and T in 14%.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Epirubicin / administration & dosage. Etoposide / administration & dosage. Female. Hematopoietic Stem Cell Transplantation / methods. Humans. Karnofsky Performance Status. Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / therapy. Male. Middle Aged. Prednisolone / administration & dosage. Prednisone / administration & dosage. Prospective Studies. Remission Induction / methods. Rituximab. Stem Cell Transplantation. Survival Analysis. Tunisia. Vincristine / administration & dosage. Young Adult

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20374978.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 3Z8479ZZ5X / Epirubicin; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VB0R961HZT / Prednisone; CEOP protocol 2; CHOEP protocol; CHOP protocol
  •  go-up   go-down


10. Amara K, Ziadi S, Hachana M, Soltani N, Korbi S, Trimeche M: DNA methyltransferase DNMT3b protein overexpression as a prognostic factor in patients with diffuse large B-cell lymphomas. Cancer Sci; 2010 Jul;101(7):1722-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diffuse large B-cell lymphomas (DLBCL) are the most common type of aggressive lymphomas, with considerable heterogeneity in clinical presentation, molecular characteristics, and outcome.
  • In conclusion, DNMT3b overexpression was identified as an independent prognostic factor for predicting shortened survival of patients with DLBCL and could be, therefore, useful in identifying patients who would benefit from aggressive therapy.
  • [MeSH-major] DNA (Cytosine-5-)-Methyltransferase / genetics. Lymphoma, B-Cell / genetics

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20398054.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.1.1.37 / DNA (Cytosine-5-)-Methyltransferase; EC 2.1.1.37 / DNA (cytosine-5-)-methyltransferase 1; EC 2.1.1.37 / DNA methyltransferase 3A; EC 2.1.1.37 / DNA methyltransferase 3B
  •  go-up   go-down


11. Wilkins K, Turner R, Dolev JC, LeBoit PE, Berger TG, Maurer TA: Cutaneous malignancy and human immunodeficiency virus disease. J Am Acad Dermatol; 2006 Feb;54(2):189-206; quiz 207-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant melanoma and squamous cell carcinoma are examples of cutaneous malignancies that have a more aggressive course in patients with HIV.
  • Others, such as basal cell carcinoma, appear more frequently in this population but do not appear to be more aggressive.
  • Cutaneous T-cell lymphoma (CTCL) is rare in this population.
  • Other types of cutaneous lymphoma and HIV-associated pseudo-CTCL are discussed.
  • [MeSH-minor] Algorithms. Animals. Anti-Retroviral Agents / administration & dosage. Anus Neoplasms / epidemiology. Anus Neoplasms / pathology. Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Herpesviridae Infections / epidemiology. Herpesvirus 8, Human / isolation & purification. Humans. Immunity, Cellular. Immunohistochemistry. Lymphoma, Large-Cell, Anaplastic / epidemiology. Lymphoma, T-Cell, Cutaneous / epidemiology. Lymphoma, T-Cell, Cutaneous / immunology. Lymphoma, T-Cell, Cutaneous / pathology. Melanoma / epidemiology. Melanoma / therapy. Papillomaviridae. Papillomavirus Infections / epidemiology. Risk Factors. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / epidemiology. Seroepidemiologic Studies

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16443048.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 274
  •  go-up   go-down


12. Dosio F, Milla P, Cattel L: EC-145, a folate-targeted Vinca alkaloid conjugate for the potential treatment of folate receptor-expressing cancers. Curr Opin Investig Drugs; 2010 Dec;11(12):1424-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Experiments in mouse tumor xenograft models have confirmed the potency of EC-145 and the curative effects of the drug conjugate were demonstrated in an aggressive lymphoma xenograft model.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Folic Acid.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21154124.001).
  • [ISSN] 2040-3429
  • [Journal-full-title] Current opinion in investigational drugs (London, England : 2000)
  • [ISO-abbreviation] Curr Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / EC145; 0 / Vinca Alkaloids; 935E97BOY8 / Folic Acid
  •  go-up   go-down


13. Kerl K, Prins C, Cerroni L, French LE: Regression of extranodal natural killer/T-cell lymphoma, nasal type with denileukin diftitox (Ontak) and bexarotene (Targretin): report of a case. Br J Dermatol; 2006 May;154(5):988-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of extranodal natural killer/T-cell lymphoma, nasal type with denileukin diftitox (Ontak) and bexarotene (Targretin): report of a case.
  • We report a patient with rapidly progressive Epstein-Barr virus-positive nasal type extranodal natural killer/T-cell lymphoma (extranodal NKTCL), treated with a combination of denileukin diftitox (Ontak) and oral bexarotene (Targretin).
  • Combination treatment with denileukin diftitox and bexarotene should be further assessed in this aggressive type of cutaneous lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell, Cutaneous / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16634908.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Diphtheria Toxin; 0 / Interleukin-2; 0 / Recombinant Fusion Proteins; 0 / Tetrahydronaphthalenes; 25E79B5CTM / denileukin diftitox; A61RXM4375 / bexarotene
  •  go-up   go-down


14. Evens AM, Roy R, Sterrenberg D, Moll MZ, Chadburn A, Gordon LI: Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy. Curr Oncol Rep; 2010 Nov;12(6):383-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PTLDs consist of a disease spectrum ranging from hyperplasia to aggressive lymphomas with 60-70% being Epstein-Barr virus positive.
  • The majority of cases are B-cell, although 10-15% are of T-cell origin or rarely Hodgkin lymphoma.

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 2006 Mar;45(3):313-8 [16283619.001]
  • [Cites] Am J Transplant. 2008 May;8(5):984-9 [18416737.001]
  • [Cites] J Clin Oncol. 2000 Nov 1;18(21):3622-32 [11054435.001]
  • [Cites] Blood. 1995 Jan 15;85(2):552-65 [7812011.001]
  • [Cites] Blood. 2009 Nov 5;114(19):4002-8 [19724053.001]
  • [Cites] Am J Transplant. 2004 Feb;4(2):222-30 [14974943.001]
  • [Cites] Blood. 2009 Nov 26;114(23):4784-91 [19759356.001]
  • [Cites] Blood. 2009 Nov 26;114(23):4792-803 [19770360.001]
  • [Cites] Transplant Proc. 1969 Mar;1(1):106-12 [4944206.001]
  • [Cites] Br J Haematol. 2010 May;149(4):569-77 [20230398.001]
  • [Cites] Transplantation. 1998 Dec 27;66(12):1770-9 [9884275.001]
  • [Cites] Transpl Infect Dis. 2001 Sep;3(3):177-85 [11493400.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):772-8 [11157030.001]
  • [Cites] Br J Haematol. 2006 Sep;134(6):602-12 [16889621.001]
  • [Cites] Transplantation. 1999 Mar 15;67(5):765-7 [10096538.001]
  • [Cites] Transplantation. 2001 Apr 27;71(8):1076-88 [11374406.001]
  • [Cites] Haematologica. 2007 Feb;92(2):273-4 [17296588.001]
  • [Cites] Transplantation. 1995 Jan 27;59(2):240-4 [7839447.001]
  • [Cites] Am J Transplant. 2005 Dec;5(12):2894-900 [16303002.001]
  • [Cites] Transplant Proc. 2005 Mar;37(2):954-5 [15848587.001]
  • [Cites] Lancet. 1984 Mar 17;1(8377):583-7 [6142304.001]
  • [Cites] Blood. 2001 Mar 15;97(6):1590-7 [11238096.001]
  • [Cites] J Clin Oncol. 2007 Nov 1;25(31):4902-8 [17971586.001]
  • [Cites] Am J Transplant. 2006 Nov;6(11):2735-42 [17049061.001]
  • [Cites] Am J Transplant. 2006 Mar;6(3):569-76 [16468968.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3137-47 [9787149.001]
  • [Cites] Diagn Mol Pathol. 2007 Sep;16(3):158-68 [17721324.001]
  • [Cites] Blood. 2010 Apr 8;115(14):2960-70 [20103780.001]
  • [Cites] Transplantation. 2005 Dec 27;80(12):1692-8 [16378063.001]
  • [Cites] Transplantation. 2002 Oct 27;74(8):1095-102 [12438953.001]
  • [Cites] J Clin Oncol. 2010 Feb 20;28(6):1038-46 [20085936.001]
  • [Cites] Bone Marrow Transplant. 2003 Feb;31(3):145-55 [12621474.001]
  • [Cites] Am J Surg Pathol. 2000 Mar;24(3):375-85 [10716151.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1604-12 [17122518.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2052-9 [9626203.001]
  • [Cites] Transplantation. 2005 Nov 15;80(9):1233-43 [16314791.001]
  • [Cites] Transpl Infect Dis. 2001 Jun;3(2):70-8 [11395972.001]
  • [Cites] Leuk Lymphoma. 2005 Feb;46(2):191-6 [15621801.001]
  • [Cites] J Clin Oncol. 2010 Nov 1;28(31):4740-6 [20837940.001]
  • [Cites] Transplantation. 1998 Dec 27;66(12):1604-11 [9884246.001]
  • [Cites] Semin Diagn Pathol. 1997 Feb;14 (1):15-26 [9044506.001]
  • [Cites] Transplantation. 1997 May 15;63(9):1200-5 [9158009.001]
  • [Cites] Transplantation. 2001 Apr 27;71(8):1065-8 [11374404.001]
  • [Cites] Am J Clin Pathol. 2005 Jan;123(1):104-12 [15762285.001]
  • [Cites] Blood. 1995 Nov 1;86(9):3333-40 [7579436.001]
  • [Cites] Bone Marrow Transplant. 2008 Jan;41(2):193-8 [17982497.001]
  • [Cites] Leuk Lymphoma. 2008 Sep;49(9):1738-44 [18798108.001]
  • [Cites] N Engl J Med. 2000 Feb 10;342(6):440-1 [10681228.001]
  • [Cites] Br J Haematol. 2008 Jan;140(2):191-6 [18173755.001]
  • [Cites] Am J Transplant. 2007 Nov;7(11):2619-25 [17868060.001]
  • [Cites] Am J Med. 1989 Feb;86(2):241-4 [2536518.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4285-90 [10759564.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3053-7 [16254143.001]
  • (PMID = 20963522.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


15. Grigoropoulos NF, Shaw AS, Hampson FA, Baglin TP, Follows GA: Incidental pulmonary emboli in lymphoma patients are associated with aggressive disease and poor prognosis. J Thromb Haemost; 2010 Dec;8(12):2835-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental pulmonary emboli in lymphoma patients are associated with aggressive disease and poor prognosis.
  • [MeSH-major] Lymphoma, Non-Hodgkin / complications. Pulmonary Embolism / complications

  • Genetic Alliance. consumer health - Pulmonary Disease.
  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Thromb Haemost. 2010 Aug;8(8):1716-22 [20546118.001]
  • (PMID = 20854375.001).
  • [ISSN] 1538-7836
  • [Journal-full-title] Journal of thrombosis and haemostasis : JTH
  • [ISO-abbreviation] J. Thromb. Haemost.
  • [Language] eng
  • [Publication-type] Comment; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


16. Emmanouilides C: Review of Y-ibritumomab tiuxetan as first-line consolidation radio-immunotherapy for B-cell follicular non-Hodgkin's lymphoma. Cancer Manag Res; 2009;1:131-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review of Y-ibritumomab tiuxetan as first-line consolidation radio-immunotherapy for B-cell follicular non-Hodgkin's lymphoma.
  • Several studies have indicated that radioimmunotherapy is an effective and clinically relevant complementary therapeutic approach for patients with B-cell non-Hodgkin's lymphoma (NHL) and may convert partial to complete response when given as consolidation after induction chemotherapy.
  • Yttrium-90((90)Y)-ibritumomab tiuxetan ((90)Y-IT, Zevalin(®), Y2B8) has documented efficacy for both indolent and aggressive NHL.
  • A recently completed randomized study for patients with follicular lymphoma has demonstrated that (90)Y-ibritumomab consolidation also produced a marked prolongation of the median time to progression from 13.5 to 37 months, while partial responders seem to derive relatively more benefit.
  • Other published and ongoing studies explore a similar use for patients with aggressive lymphoma.
  • In conclusion, the documented benefit of radioimmunotherapy should be viewed in the context of the goals of treatment and the changing standards of care for lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hell J Nucl Med. 2004 Jan-Apr;7(1):39-43 [16868640.001]
  • [Cites] Blood. 2007 Jul 1;110(1):54-8 [17387223.001]
  • [Cites] Cancer Biother Radiopharm. 2007 Oct;22(5):684-91 [17979571.001]
  • [Cites] J Clin Exp Hematop. 2007 Nov;47(2):43-60 [18040144.001]
  • [Cites] Cancer. 2008 Feb 15;112(4):856-62 [18189293.001]
  • [Cites] Ann Oncol. 2008 Apr;19(4):769-73 [18303033.001]
  • [Cites] Hell J Nucl Med. 2008 Jan-Apr;11(1):12-5 [18392220.001]
  • [Cites] Leuk Lymphoma. 2008 Jul;49(7):1263-73 [18604715.001]
  • [Cites] Cancer. 2002 Feb 15;94(4 Suppl):1349-57 [11877765.001]
  • [Cites] J Clin Oncol. 2001 Oct 1;19(19):3918-28 [11579112.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3262-9 [12149300.001]
  • [Cites] J Nucl Med. 2003 Mar;44(3):465-74 [12621016.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4429-31 [15016644.001]
  • [Cites] Clin Lymphoma. 2004 Dec;5(3):202-4 [15636698.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4285-92 [17709799.001]
  • [Cites] Lancet Oncol. 2008 Apr;9(4):352-8 [18342572.001]
  • [Cites] J Clin Oncol. 2009 Apr 1;27(10):1607-14 [19255334.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14(21):7088-94 [18981007.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1606-12 [12738671.001]
  • [Cites] Semin Oncol. 2003 Aug;30(4):531-44 [12939722.001]
  • [Cites] Cancer Treat Rev. 2004 Apr;30(2):165-72 [15023434.001]
  • [Cites] Cancer Biother Radiopharm. 2005 Apr;20(2):185-8 [15869453.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5696-704 [16110029.001]
  • [Cites] Leuk Lymphoma. 2006 Apr;47(4):629-36 [16690521.001]
  • [Cites] Blood. 2006 Jul 15;108(2):777; author reply 777-8 [16822910.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5147-50 [18854559.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5156-64 [18854568.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3793-803 [10577851.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2453-63 [12011122.001]
  • (PMID = 21188131.001).
  • [ISSN] 1179-1322
  • [Journal-full-title] Cancer management and research
  • [ISO-abbreviation] Cancer Manag Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3004670
  • [Keywords] NOTNLM ; 90Y-ibritumomab tiuxetan / consolidation / follicular lymphoma / radioimmunotherapy
  •  go-up   go-down


17. Bilbao EA, Chirife AM, Florio D, Giménez LB, Marino L, Rosso DA: [Hematodermic CD4+ CD56+ neoplasm in childhood]. Medicina (B Aires); 2008;68(2):147-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hematodermic CD4+ CD56+ neoplasm with plasmacytoid dendritic cell phenotype is a rare and aggressive neoplasm recently recognized by the WHO-EORTC classification.
  • [MeSH-major] Antigens, CD4. Antigens, CD56. Biomarkers, Tumor. Lymphoma / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18499965.001).
  • [ISSN] 0025-7680
  • [Journal-full-title] Medicina
  • [ISO-abbreviation] Medicina (B Aires)
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Argentina
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / Antigens, CD56; 0 / Biomarkers, Tumor; 0 / CLEC4C protein, human; 0 / Interleukin-3 Receptor alpha Subunit; 0 / Lectins, C-Type; 0 / Membrane Glycoproteins; 0 / Receptors, Immunologic
  •  go-up   go-down


18. Dijkman R, Tensen CP, Buettner M, Niedobitek G, Willemze R, Vermeer MH: Primary cutaneous follicle center lymphoma and primary cutaneous large B-cell lymphoma, leg type, are both targeted by aberrant somatic hypermutation but demonstrate differential expression of AID. Blood; 2006 Jun 15;107(12):4926-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous follicle center lymphoma and primary cutaneous large B-cell lymphoma, leg type, are both targeted by aberrant somatic hypermutation but demonstrate differential expression of AID.
  • We assessed primary cutaneous large B-cell lymphoma, leg type (PCLBCL, leg type; n = 13), and primary cutaneous follicle center lymphoma (PCFCL; n = 19) for somatic hypermutation (SHM) of BCL6, and aberrant SHM of MYC, RhoH/TTF, and PAX5.
  • Our results suggest that (aberrant) SHM may contribute to the pathogenesis of PCLBCL, leg type, and PCFCL and is not restricted to diffuse large B-cell lymphomas with an aggressive clinical behavior.
  • [MeSH-major] Cytosine Deaminase / genetics. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Leukemic. Leg. Lymphoma, B-Cell / genetics. Lymphoma, Follicular / genetics. Neoplasm Proteins / genetics. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16507780.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; EC 3.5.4.- / AICDA (activation-induced cytidine deaminase); EC 3.5.4.1 / Cytosine Deaminase; EC 3.5.4.5 / Cytidine Deaminase
  •  go-up   go-down


19. Spitzer TR, Ambinder RF, Lee JY, Kaplan LD, Wachsman W, Straus DJ, Aboulafia DM, Scadden DT: Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant; 2008 Jan;14(1):59-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020.
  • Intensive chemotherapy for human immunodeficiency virus (HIV)-associated non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) has resulted in durable remissions in a substantial proportion of patients.
  • Based on a favorable experience with dose-reduced high-dose busulfan, cyclophosphamide, and AuSCT for older patients with non-HIV-associated aggressive lymphomas, an AIDS Malignancy Consortium multicenter trial was undertaken using the same dose-reduced busulfan and cyclophosphamide preparative regimen with AuSCT for recurrent HIV-associated NHL and HL.
  • This multi-institutional trial demonstrates that a regimen of dose-reduced high-dose busulfan, cyclophosphamide, and AuSCT is well tolerated and is associated with favorable disease-free survival (DFS) and OS probabilities for selected patients with HIV-associated NHL and HL.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18158962.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01CA070062; United States / NCI NIH HHS / CA / U01 CA070047; United States / NCI NIH HHS / CA / U01 CA070019; United States / NCI NIH HHS / CA / U01 CA083035; United States / NCI NIH HHS / CA / U01 CA083118; United States / NCI NIH HHS / CA / U01 CA071375; United States / NCI NIH HHS / CA / U01CA083216; United States / NCI NIH HHS / CA / U01CA083118; United States / NCI NIH HHS / CA / U01CA071375; United States / NCI NIH HHS / CA / U01CA070047; United States / NCI NIH HHS / CA / U01CA070054; United States / NCI NIH HHS / CA / U01 CA070054; United States / NCI NIH HHS / CA / U01CA070019; United States / NCI NIH HHS / CA / R01 CA095423; United States / NCI NIH HHS / CA / U01 CA070062; United States / NCI NIH HHS / CA / U01CA083035; United States / NCI NIH HHS / CA / U01 CA121947; United States / NCI NIH HHS / CA / P50 CA096888
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; G1LN9045DK / Busulfan
  • [Other-IDs] NLM/ NIHMS281894; NLM/ PMC4524737
  •  go-up   go-down


21. McNutt DM, Holdsworth MT, Wong C, Hanrahan JD, Winter SS: Rasburicase for the management of tumor lysis syndrome in neonates. Ann Pharmacother; 2006 Jul-Aug;40(7-8):1445-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite several doses of intravenous rasburicase (2 doses of 0.1 mg/kg and 4 doses of 0.2 mg/kg), as well as aggressive supportive therapy, the infant died of complications arising from uncontrolled TLS.
  • [MeSH-minor] Adrenal Gland Neoplasms / blood. Adrenal Gland Neoplasms / complications. Adrenal Gland Neoplasms / congenital. Adrenal Gland Neoplasms / drug therapy. Antineoplastic Agents / adverse effects. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Female. Humans. Infant, Newborn. Male. Neuroblastoma / blood. Neuroblastoma / complications. Neuroblastoma / congenital. Neuroblastoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Uric Acid / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16868218.001).
  • [ISSN] 1060-0280
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 268B43MJ25 / Uric Acid; EC 1.7.3.3 / Urate Oxidase; EC 1.7.3.3. / rasburicase
  •  go-up   go-down


22. Verdonck LF, Notenboom A, de Jong DD, MacKenzie MA, Verhoef GE, Kramer MH, Ossenkoppele GJ, Doorduijn JK, Sonneveld P, van Imhoff GW: Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). Blood; 2007 Apr 1;109(7):2759-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON).
  • Optimal dose and timing of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy for aggressive non-Hodgkin lymphoma (NHL) is still an unresolved issue.
  • We assessed whether dose intensifications with cyclophosphamide and doxorubicin might improve outcome in younger patients with intermediate-risk aggressive NHL.
  • These data suggest that I-CHOP might be preferable to standard CHOP in younger patients with low-intermediate-risk aggressive NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Granulocyte Colony-Stimulating Factor / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17132720.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


23. Liu CY, Teng HW, Lirng JF, Chiou TJ, Chen PM, Hsiao LT: Sustained remission and long-term survival of secondary central nervous system involvement by aggressive B-cell lymphoma after combination treatment of systemic high-dose chemotherapy and intrathecal rituximab. Leuk Lymphoma; 2008 Oct;49(10):2018-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained remission and long-term survival of secondary central nervous system involvement by aggressive B-cell lymphoma after combination treatment of systemic high-dose chemotherapy and intrathecal rituximab.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy

  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18728965.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


24. Cooley LD, Chenevert S, Shuster JJ, Johnston DA, Mahoney DH, Carroll AJ, Devidas M, Linda SB, Lauer SJ, Camitta BM: Prognostic significance of cytogenetically detected chromosome 21 anomalies in childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study. Cancer Genet Cytogenet; 2007 Jun;175(2):117-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The frequency of an adverse outcome was comparable to other poor prognosis subgroups such as hypodiploidy (<45 chromosomes), t(9;22), or t(4;11), all of which have been targeted for aggressive therapy even if the case is otherwise standard risk.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 21 / genetics. Cytogenetic Analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17556067.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA030969; United States / NCI NIH HHS / CA / U10 CA098543
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Peterson BA, Johnson J, Shipp MA, Barcos M, Gockerman JP, Canellos GP, Cancer and Leukemia Group B 9351: High dose CHOP: a phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351. Leuk Lymphoma; 2007 May;48(5):870-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High dose CHOP: a phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351.
  • Cyclophosphamide and doxorubicin, two important drugs in the treatment of lymphoma, exhibit a relationship between dose and fractional cell kill, and because of their toxicity profiles, they are candidates for significant dose escalation.
  • We performed a phase II trial to determine the response rate, toxicity, and feasibility of escalated doses of both drugs as part of high dose CHOP in diffuse aggressive lymphoma.
  • Patients who had advanced, previously untreated diffuse aggressive lymphomas (IWF E-H) and an International Prognostic Index of intermediate to high risk were eligible.
  • Persistent or relapsed lymphoma was the overwhelming cause of death.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2007 May;48(5):845-6 [17487722.001]
  • (PMID = 17487729.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA02599; United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / CA04326; United States / NCI NIH HHS / CA / CA04457; United States / NCI NIH HHS / CA / CA08025; United States / NCI NIH HHS / CA / CA12499; United States / NCI NIH HHS / CA / CA16450; United States / NCI NIH HHS / CA / CA21060; United States / NCI NIH HHS / CA / CA26806; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA31983; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA35279; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / CA47555; United States / NCI NIH HHS / CA / CA47559; United States / NCI NIH HHS / CA / CA47575; United States / NCI NIH HHS / CA / CA47577; United States / NCI NIH HHS / CA / CA47642; United States / NCI NIH HHS / CA / CA60138; United States / NCI NIH HHS / CA / CA77440
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


26. Yamamoto S, Nakase H, Yamashita K, Matsuura M, Takada M, Kawanami C, Chiba T: Gastrointestinal follicular lymphoma: review of the literature. J Gastroenterol; 2010 Apr;45(4):370-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal follicular lymphoma: review of the literature.
  • Gastrointestinal follicular lymphoma (GI-FL) is a relatively rare disease, accounting for only 1%-3.6% of gastrointestinal non-Hodgkin's lymphoma.
  • FL is a low-grade lymphoma that usually develops very slowly.
  • If the lymphoma causes no symptoms, immediate treatment may not be necessary.
  • Thus, whether to initiate aggressive therapy or whether to continue watchful waiting in patients with GI-FL is a critically important decision.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Neoplasms / therapy. Lymphoma, Follicular / therapy

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Kyoto University Research Information Repository - Articles. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2005 May;128(6):1579-605 [15887153.001]
  • [Cites] Int J Gastrointest Cancer. 2005;36(2):113-9 [16648662.001]
  • [Cites] Blood. 2000 Feb 1;95(3):783-9 [10648386.001]
  • [Cites] Ann Oncol. 2006 May;17 (5):780-4 [16497824.001]
  • [Cites] Leukemia. 1993 Feb;7(2):268-73 [8426481.001]
  • [Cites] Dig Dis Sci. 2001 Mar;46(3):567-70 [11318534.001]
  • [Cites] Dig Dis Sci. 2007 Apr;52(4):1031-5 [17353993.001]
  • [Cites] Arch Pathol Lab Med. 2008 Aug;132(8):1355-61 [18684042.001]
  • [Cites] Lancet. 1995 Jun 24;345(8965):1591-4 [7783535.001]
  • [Cites] Arch Dermatol. 2001 Apr;137(4):432-9 [11295923.001]
  • [Cites] Endoscopy. 2007 Feb;39 Suppl 1:E86-7 [17440873.001]
  • [Cites] Histopathology. 1984 Jul;8(4):641-56 [6479906.001]
  • [Cites] Ann Oncol. 2003 Apr;14(4):623-9 [12649111.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1417-23 [15494430.001]
  • [Cites] Cancer. 1961 Mar-Apr;14:249-57 [13695582.001]
  • [Cites] Intern Med. 2007;46(3):141-2 [17268132.001]
  • [Cites] Recent Results Cancer Res. 2000;156:116-24 [10802871.001]
  • [Cites] J Mol Diagn. 2007 Sep;9(4):530-7 [17652637.001]
  • [Cites] N Engl J Med. 1987 Jan 8;316(2):79-84 [3537802.001]
  • [Cites] Hepatogastroenterology. 2007 Sep;54(78):1658-61 [18019688.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):105-13 [12507894.001]
  • [Cites] J Clin Pathol. 2008 Mar;61(3):377-81 [17601964.001]
  • [Cites] J Clin Gastroenterol. 2008 Oct;42(9):997-1002 [18719510.001]
  • [Cites] Gastrointest Endosc. 2008 Apr;67(4):763-5 [18207144.001]
  • [Cites] Leukemia. 2000 Sep;14(9):1563-9 [10995001.001]
  • [Cites] Am J Clin Oncol. 2003 Aug;26(4):408-10 [12902896.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1258-65 [15126323.001]
  • [Cites] Can J Gastroenterol. 1997 Jan-Feb;11(1):31-4 [9113795.001]
  • [Cites] Br J Dermatol. 2001 Apr;144(4):735-44 [11298531.001]
  • [Cites] Histopathology. 2005 Nov;47(5):467-78 [16241994.001]
  • [Cites] Am J Clin Pathol. 2005 Sep;124(3):421-9 [16191511.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Jan;21(1):17-29 [9443038.001]
  • [Cites] Mod Pathol. 2000 May;13(5):586-90 [10824932.001]
  • [Cites] Lancet. 1991 Nov 9;338(8776):1175-6 [1682595.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8018-24 [16204012.001]
  • [Cites] Endoscopy. 2009 Feb;41(2):175-8 [19214900.001]
  • [Cites] Am J Surg Pathol. 1996 Apr;20(4):442-52 [8604811.001]
  • [Cites] Br J Haematol. 2004 Sep;126(6):772-84 [15352980.001]
  • [Cites] Am J Pathol. 1992 Jun;140(6):1327-35 [1376556.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Aug;5(8):e30 [17625984.001]
  • [Cites] Histopathology. 1998 Feb;32(2):116-25 [9543667.001]
  • [Cites] Ann Hematol. 2004 May;83(5):276-8 [15060746.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):484-8 [9130997.001]
  • [Cites] Virchows Arch. 2002 Dec;441(6):614-7 [12461620.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Feb;33(2):213-6 [11793448.001]
  • [Cites] Endoscopy. 2008 Apr;40(4):343-6 [18067068.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3922-8 [10845929.001]
  • [Cites] Ann Hematol. 2002 Apr;81(4):228-31 [11976827.001]
  • [Cites] Gut. 2003 Jun;52 Suppl 4:iv48-50 [12746269.001]
  • [Cites] Haematologica. 1992 Mar-Apr;77(2):156-61 [1398301.001]
  • [Cites] Radiol Clin North Am. 2004 Nov;42(6):1083-100 [15488559.001]
  • [Cites] Gastrointest Endosc. 2001 Jul;54(1):92-6 [11427853.001]
  • [Cites] Springer Semin Immunopathol. 1990;12(2-3):239-50 [2205943.001]
  • [Cites] Mod Pathol. 2009 Jul;22(7):940-9 [19396151.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):717-20 [9739436.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Nov;5(11):A24 [17981239.001]
  • [Cites] Intern Med. 2007;46(11):705-9 [17541220.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):216-24 [11812943.001]
  • [Cites] Cancer. 2003 May 15;97(10):2462-73 [12733145.001]
  • [Cites] Cancer. 2007 Aug 1;110(3):652-9 [17582800.001]
  • [Cites] Histopathology. 2004 Mar;44(3):268-76 [14987231.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):175-83 [16721817.001]
  • [Cites] Eur J Cancer. 1991;27(10):1201-8 [1835586.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3725-32 [16123223.001]
  • [Cites] Lancet. 2003 Aug 16;362(9383):516-22 [12932382.001]
  • [Cites] Acta Oncol. 2001;40(2-3):213-23 [11441933.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1986-92 [17420513.001]
  • [Cites] J Clin Gastroenterol. 2002 Feb;34(2):155-9 [11782611.001]
  • [Cites] Clin Transl Oncol. 2007 Jul;9(7):471-2 [17652063.001]
  • [Cites] Br J Cancer. 1993 Apr;67(4):776-82 [8471435.001]
  • [Cites] Science. 1985 Jun 21;228(4706):1440-3 [3874430.001]
  • [Cites] Endoscopy. 2007 Feb;39 Suppl 1:E26-7 [17285496.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2456-64 [9310498.001]
  • [Cites] Arch Pathol Lab Med. 2004 Sep;128(9):1035-8 [15335250.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):140-7 [7799014.001]
  • [Cites] J Clin Oncol. 1993 Feb;11(2):218-24 [8426197.001]
  • [Cites] Hum Pathol. 1999 May;30(5):581-7 [10333231.001]
  • [Cites] N Engl J Med. 1994 May 5;330(18):1267-71 [8145781.001]
  • [Cites] Lancet. 1993 Sep 4;342(8871):575-7 [8102719.001]
  • [Cites] Hematol Oncol. 1983 Apr-Jun;1(2):187-92 [6376315.001]
  • [Cites] Br J Haematol. 2001 Dec;115(4):793-800 [11843811.001]
  • [Cites] N Engl J Med. 2004 Jan 15;350(3):239-48 [14724303.001]
  • [Cites] Lancet. 1993 Sep 4;342(8871):571-4 [8102718.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 17;89(18):1350-5 [9308704.001]
  • [Cites] Gastrointest Endosc. 2009 Jan;69(1):158-9; discussion 159 [19111697.001]
  • [Cites] J Clin Oncol. 1986 Oct;4(10):1470-80 [3531422.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):875-83 [11420458.001]
  • [Cites] Endoscopy. 2010 Jan;42(1):86; author reply 87 [20066597.001]
  • [Cites] Gastroenterology. 2003 Nov;125(5):1556; author reply 1556-7 [14628813.001]
  • [Cites] J Mol Diagn. 2003 Aug;5(3):168-75 [12876207.001]
  • [Cites] Blood. 1986 Oct;68(4):837-45 [3530348.001]
  • [Cites] Blood. 2002 May 15;99(10):3806-12 [11986240.001]
  • [Cites] J Exp Med. 1986 Jul 1;164(1):315-20 [3014037.001]
  • [Cites] Intern Med. 2006;45(5):309-11 [16596000.001]
  • [Cites] Am J Surg Pathol. 2000 Dec;24(12):1641-9 [11117785.001]
  • [Cites] Pathol Res Pract. 2007;203(9):691-4 [17643847.001]
  • [Cites] Jpn J Clin Oncol. 2008 Aug;38(8):547-52 [18687756.001]
  • [Cites] Cell. 1986 Oct 10;47(1):19-28 [2875799.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3034-44 [16397126.001]
  • [Cites] Am J Surg Pathol. 1983 Jun;7(4):363-72 [6869665.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] J Clin Gastroenterol. 2002 Sep;35(3):285-6 [12192212.001]
  • [Cites] Endoscopy. 2007 Feb;39 Suppl 1:E39 [17285511.001]
  • [Cites] Mod Pathol. 1998 Nov;11(11):1046-51 [9831200.001]
  • [Cites] Science. 1968 Dec 20;162(3860):1396-7 [4177362.001]
  • [Cites] Gut. 2004 Jan;53(1):34-7 [14684573.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2780-95 [9704731.001]
  • [Cites] World J Gastroenterol. 2004 Sep 1;10(17):2602-4 [15300917.001]
  • [Cites] J Gastroenterol. 2003;38(6):584-7 [12856675.001]
  • [Cites] Ann Oncol. 1994 May;5(5):397-400 [8075046.001]
  • [Cites] Am J Surg Pathol. 2000 May;24(5):688-93 [10800987.001]
  • [Cites] Hum Pathol. 2007 Feb;38(2):365-72 [17134735.001]
  • [Cites] Ann Intern Med. 1995 May 15;122(10):767-9 [7717599.001]
  • [Cites] Int J Oncol. 2001 Apr;18(4):743-8 [11251169.001]
  • [Cites] Cancer. 1978 Aug;42(2):693-707 [354774.001]
  • [Cites] Cell. 1985 Jul;41(3):899-906 [3924412.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Intern Med. 2008;47(13):1277-8 [18591856.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1852-6 [12200703.001]
  • [Cites] Br J Surg. 1961 Jul;49:80-9 [13884035.001]
  • [Cites] J Gastroenterol. 2003;38(5):512-3 [12768397.001]
  • [Cites] Endoscopy. 2008 Sep;40 Suppl 2:E8-9 [18278712.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2499-505 [10561315.001]
  • [Cites] Nature. 2000 May 25;405(6785):417 [10839527.001]
  • (PMID = 20084529.001).
  • [ISSN] 1435-5922
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 126
  •  go-up   go-down


27. Armitage JO, Hsi ED, Foss FM: Clinical roundtable monograph. T-cell lymphoma: therapeutic overview and disease state awareness. Clin Adv Hematol Oncol; 2010 Dec;8(12 Suppl 22):1-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical roundtable monograph. T-cell lymphoma: therapeutic overview and disease state awareness.
  • With the exception of a few subtypes that are associated with a more indolent course, the majority of T-cell lymphomas are aggressive in nature.
  • Patients with peripheral T-cell lymphomas (PTCL) have an especially poor prognosis, due both to the aggressive disease course as well as the lack of effective treatments.
  • There is no true standard of care for PTCL, and this aggressive disease has historically been treated with therapeutic regimens designed for B-cell lymphomas, such as the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21491667.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


28. Pezeshkpoor F, Yazdanpanah MJ, Shirdel A: Specific cutaneous manifestations in adult T-cell leukemia/lymphoma. Int J Dermatol; 2008 Apr;47(4):359-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Specific cutaneous manifestations in adult T-cell leukemia/lymphoma.
  • BACKGROUND: Adult T-cell leukemia/lymphoma (ATLL) is an aggressive malignancy which may occur in individuals infected with human T-cell lymphotropic virus type-I (HTLV-I).
  • As specific cutaneous manifestations of lymphoma may occur in a significant number of patients, we studied these manifestations in ATLL patients admitted to the Hematology and Dermatology Departments of Ghaem Hospital, Mashhad, Iran, during 1995-2004.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / pathology. Leukemic Infiltration. Skin / pathology

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18377598.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Wedderburn LR, Rider LG: Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment. Best Pract Res Clin Rheumatol; 2009 Oct;23(5):665-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aggressive treatment approaches, including multiple initial therapies, as well as new drugs and biological therapies for refractory disease, offer promise of improved outcomes and less corticosteroid-related toxicity.

  • Genetic Alliance. consumer health - Dermatomyositis.
  • Genetic Alliance. consumer health - Juvenile dermatomyositis.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arthritis Rheum. 2008 Feb;58(2):571-6 [18240225.001]
  • [Cites] Arthritis Rheum. 2008 Feb 15;59(2):222-6 [18240180.001]
  • [Cites] Arthritis Rheum. 2008 Feb 15;59(2):214-21 [18240194.001]
  • [Cites] Medicine (Baltimore). 2008 Mar;87(2):70-86 [18344805.001]
  • [Cites] Rheumatology (Oxford). 2008 Apr;47(4):526-9 [18304939.001]
  • [Cites] Arthritis Rheum. 2008 Mar 15;59(3):352-6 [18311761.001]
  • [Cites] Rheumatology (Oxford). 2008 Jun;47(6):877-80 [18403404.001]
  • [Cites] Lancet. 2008 Jun 28;371(9631):2201-12 [18586175.001]
  • [Cites] Arthritis Rheum. 2008 Jul 15;59(7):989-95 [18576304.001]
  • [Cites] Br J Dermatol. 2008 Sep;159(4):887-94 [18616782.001]
  • [Cites] Clin Rheumatol. 2008 Nov;27(11):1469-71 [18716733.001]
  • [Cites] Arthritis Rheum. 2008 Oct;58(10):3247-54 [18821667.001]
  • [Cites] Arthritis Rheum. 2008 Oct;58(10):3239-46 [18821675.001]
  • [Cites] Arthritis Rheum. 2008 Nov;58(11):3585-92 [18975314.001]
  • [Cites] Ann Rheum Dis. 2008 Dec;67(12):1670-7 [18272672.001]
  • [Cites] Arthritis Rheum. 2008 Dec;58(12):3941-50 [19035492.001]
  • [Cites] Annu Rev Immunol. 2009;27:363-91 [19302045.001]
  • [Cites] Dermatol Online J. 2009;15(2):1 [19336018.001]
  • [Cites] Arthritis Rheum. 2009 Apr;60(4):1160-72 [19333937.001]
  • [Cites] Arthritis Rheum. 2009 Apr 15;61(4):509-17 [19333974.001]
  • [Cites] Muscle Nerve. 2009 May;39(5):674-82 [19229963.001]
  • [Cites] Rheumatology (Oxford). 2009 Jun;48(6):607-12 [19439503.001]
  • [Cites] Arthritis Rheum. 2009 Jun;60(6):1807-14 [19479859.001]
  • [Cites] Arthritis Rheum. 2009 Jun;60(6):1825-30 [19479872.001]
  • [Cites] Leuk Lymphoma. 2009 Jul;50(7):1083-95 [19399690.001]
  • [Cites] Am J Pathol. 2009 Sep;175(3):1030-40 [19700752.001]
  • [Cites] Rheumatology (Oxford). 2009 Oct;48(10):1213-7 [19690132.001]
  • [Cites] Arthritis Rheum. 2009 Nov;60(11):3425-35 [19877055.001]
  • [Cites] J Pediatr. 2009 Dec;155(6):882-7 [19643439.001]
  • [Cites] Arthritis Rheum. 2005 Oct;52(10):3175-80 [16200621.001]
  • [Cites] JAMA. 2005 Nov 2;294(17):2170-1 [16264157.001]
  • [Cites] Arthritis Rheum. 2005 Nov;52(11):3570-8 [16255046.001]
  • [Cites] Medicine (Baltimore). 2006 Mar;85(2):111-27 [16609350.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):9209-14 [10922072.001]
  • [Cites] Arthritis Rheum. 2000 Aug;43(8):1866-73 [10943878.001]
  • [Cites] Arthritis Rheum. 2000 Oct;43(10):2368-77 [11037898.001]
  • [Cites] Rheumatology (Oxford). 2001 Nov;40(11):1262-73 [11709610.001]
  • [Cites] J Immunol. 2002 Apr 15;168(8):4154-63 [11937576.001]
  • [Cites] J Exp Med. 2002 Sep 16;196(6):781-91 [12235211.001]
  • [Cites] Rheum Dis Clin North Am. 2002 Nov;28(4):935-77 [12506779.001]
  • [Cites] Arthritis Rheum. 2003 Feb 15;49(1):7-15 [12579588.001]
  • [Cites] Arthritis Rheum. 2003 Jun 15;49(3):300-5 [12794783.001]
  • [Cites] Rheumatology (Oxford). 2003 Dec;42(12):1452-9 [12832713.001]
  • [Cites] J Rheumatol. 2004 Mar;31(3):605-9 [14994413.001]
  • [Cites] Rheumatology (Oxford). 2004 Apr;43(4):491-6 [14722349.001]
  • [Cites] J Immunol. 2004 Apr 15;172(8):5041-6 [15067086.001]
  • [Cites] J Rheumatol. 2004 Apr;31(4):801-7 [15088312.001]
  • [Cites] Rheumatology (Oxford). 2004 May;43(5):603-8 [14983103.001]
  • [Cites] Best Pract Res Clin Rheumatol. 2004 Jun;18(3):345-58 [15158745.001]
  • [Cites] Expert Opin Pharmacother. 2004 Jul;5(7):1509-15 [15212601.001]
  • [Cites] Arthritis Rheum. 2004 Jul;50(7):2281-90 [15248228.001]
  • [Cites] J Rheumatol. 2004 Aug;31(8):1644-9 [15290747.001]
  • [Cites] N Engl J Med. 1975 Feb 13;292(7):344-7 [1090839.001]
  • [Cites] Lancet. 1977 Dec 10;2(8050):1238 [73944.001]
  • [Cites] Ann Neurol. 1990 Apr;27(4):343-56 [2353792.001]
  • [Cites] Hum Immunol. 1991 Dec;32(4):235-40 [1783570.001]
  • [Cites] Arthritis Rheum. 1995 Oct;38(10):1513-8 [7575702.001]
  • [Cites] Br J Rheumatol. 1995 Aug;34(8):732-6 [7551657.001]
  • [Cites] J Rheumatol. 1996 Oct;23(10):1794-7 [8895161.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3195-9 [9096369.001]
  • [Cites] Arthritis Rheum. 1997 May;40(5):865-74 [9153548.001]
  • [Cites] Rheum Dis Clin North Am. 1997 Aug;23(3):619-55 [9287380.001]
  • [Cites] Lancet. 1999 May 22;353(9166):1762-3 [10347992.001]
  • [Cites] Arthritis Rheum. 2005 Feb;52(2):601-7 [15692974.001]
  • [Cites] J Exp Med. 2005 Feb 21;201(4):591-601 [15728237.001]
  • [Cites] Rheumatology (Oxford). 2005 Mar;44(3):386-9 [15572389.001]
  • [Cites] Arthritis Rheum. 2005 Apr 15;53(2):166-72 [15818654.001]
  • [Cites] Drugs. 2005;65(10):1355-65 [15977968.001]
  • [Cites] Arthritis Rheum. 2005 Aug 15;53(4):558-64 [16082634.001]
  • [Cites] Arthritis Rheum. 2005 Sep;52(9):2607-15 [16142757.001]
  • [Cites] Autoimmunity. 2006 May;39(3):197-203 [16769653.001]
  • [Cites] Autoimmunity. 2006 May;39(3):223-32 [16769656.001]
  • [Cites] Rheumatology (Oxford). 2006 Aug;45(8):990-3 [16467366.001]
  • [Cites] Clin Immunol. 2006 Sep;120(3):319-25 [16859997.001]
  • [Cites] Rheumatology (Oxford). 2006 Oct;45(10):1255-60 [16567354.001]
  • [Cites] Arthritis Rheum. 2006 Nov;54(11):3682-9 [17075819.001]
  • [Cites] Arthritis Rheum. 2006 Dec;54(12):3979-87 [17133612.001]
  • [Cites] Autoimmun Rev. 2007 Mar;6(4):241-7 [17317616.001]
  • [Cites] Arthritis Rheum. 2007 May;56(5):1658-68 [17469160.001]
  • [Cites] Mol Med. 2007 Jan-Feb;13(1-2):59-68 [17515957.001]
  • [Cites] Arch Dermatol. 2007 Jun;143(6):763-7 [17576943.001]
  • [Cites] Rheumatology (Oxford). 2007 Aug;46(8):1363-6 [17569746.001]
  • [Cites] Rheumatology (Oxford). 2007 Sep;46(9):1411-6 [17586554.001]
  • [Cites] Arthritis Rheum. 2007 Aug;56(8):2719-28 [17665425.001]
  • [Cites] Rheumatology (Oxford). 2007 Oct;46(10):1606-11 [17890275.001]
  • [Cites] Arthritis Rheum. 2007 Sep;56(9):3112-24 [17763410.001]
  • [Cites] Arthritis Rheum. 2007 Sep;56(9):3107-11 [17763414.001]
  • [Cites] Arthritis Rheum. 2007 Oct 15;57(7):1183-91 [17907236.001]
  • [Cites] Arthritis Rheum. 2007 Oct 15;57(7):1192-201 [17907237.001]
  • [Cites] Rheumatology (Oxford). 2007 Dec;46(12):1786-91 [18003662.001]
  • [Cites] Arthritis Rheum. 2008 Jan 15;59(1):4-13 [18163404.001]
  • [Cites] Br J Dermatol. 2008 Feb;158(2):345-50 [18067478.001]
  • [Cites] Rheumatology (Oxford). 2008 Mar;47(3):324-8 [18238791.001]
  • (PMID = 19853831.001).
  • [ISSN] 1532-1770
  • [Journal-full-title] Best practice & research. Clinical rheumatology
  • [ISO-abbreviation] Best Pract Res Clin Rheumatol
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / Z01 ES101074-05; United States / Intramural NIH HHS / / Z01 ES101081-06; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Glucocorticoids; 0 / Immunosuppressive Agents
  • [Number-of-references] 101
  • [Other-IDs] NLM/ NIHMS136423; NLM/ PMC2774891
  •  go-up   go-down


30. Belloni-Fortina A, Montesco MC, Piaserico S, Bordignon M, Tona F, Feltrin G, Alaibac M: Primary cutaneous CD30+ anaplastic large cell lymphoma in a heart transplant patient: case report and literature review. Acta Derm Venereol; 2009;89(1):74-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous CD30+ anaplastic large cell lymphoma in a heart transplant patient: case report and literature review.
  • We describe here a rare primary cutaneous T-cell lymphoma CD30+ arising in a heart transplant patient who had a nodule on the right leg, several years after heart transplantation.
  • The morphology and immunohistochemical findings were consistent with a CD30+ anaplastic large cell lymphoma with a T-cell phenotype.
  • In this patient, the presence of a solitary lesion and the lack of systemic involvement represented the main factors taken into account in choosing the therapy and the patient was therefore treated using a non-aggressive approach, although with systemic immunosuppression.
  • In conclusion, the diagnosis of a CD30+ anaplastic large cell lymphoma in transplant recipients does not imply aggressive clinical behaviour by the lymphoma.
  • [MeSH-major] Antigens, CD30 / analysis. Heart Transplantation. Lymphoma, T-Cell, Cutaneous / etiology. Skin Neoplasms / etiology


31. Oshiro A, Tagawa H, Ohshima K, Karube K, Uike N, Tashiro Y, Utsunomiya A, Masuda M, Takasu N, Nakamura S, Morishima Y, Seto M: Identification of subtype-specific genomic alterations in aggressive adult T-cell leukemia/lymphoma. Blood; 2006 Jun 1;107(11):4500-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of subtype-specific genomic alterations in aggressive adult T-cell leukemia/lymphoma.
  • Aggressive adult T-cell leukemia/lymphoma (ATLL) such as acute and lymphoma types are fatal diseases with poor prognosis.
  • We performed array-based comparative genomic hybridization for 17 acute and 49 lymphoma cases as well as real-time quantitative polymerase chain reaction (PCR) to identify the target genes of recurrently amplified regions.
  • Comparison of the genome profiles of acute and lymphoma types revealed that the lymphoma type had significantly more frequent gains at 1q, 2p, 4q, 7p, and 7q, and losses of 10p, 13q, 16q, and 18p, whereas the acute type showed a gain of 3/3p.
  • Of the recurrent high-level amplifications found at 1p36, 6p25, 7p22, 7q, and 14q32 in the lymphoma type, we were able to demonstrate that CARMA1 is a possible target gene of the 7p22 amplification for the lymphoma type but not for the acute type.
  • Furthermore, we found BCL11B overexpression in the acute type regardless of the 14q32 gain/amplification, but no or low expression of the gene in the lymphoma type.
  • These results suggest that acute and lymphoma types are genomically distinct subtypes, and thus may develop tumors via distinct genetic pathways.
  • [MeSH-major] Gene Amplification. Genome, Human. Leukemia-Lymphoma, Adult T-Cell / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis Regulatory Proteins / genetics. CARD Signaling Adaptor Proteins. Chromosomes. DNA-Binding Proteins / genetics. Female. Gene Dosage. Gene Expression Regulation, Neoplastic. Guanylate Cyclase / genetics. Humans. Lymphoma / genetics. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Polymerase Chain Reaction. Repressor Proteins / genetics. Tumor Suppressor Proteins / genetics

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16484591.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / BCL11B protein, human; 0 / CARD Signaling Adaptor Proteins; 0 / DNA-Binding Proteins; 0 / Repressor Proteins; 0 / Tumor Suppressor Proteins; EC 4.6.1.2 / CARD11 protein, human; EC 4.6.1.2 / Guanylate Cyclase
  •  go-up   go-down


32. Kwong YL: Natural killer-cell malignancies: diagnosis and treatment. Leukemia; 2005 Dec;19(12):2186-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previously known as polymorphic reticulosis or angiocentric T-cell lymphomas, they are classified by the World Health Organization as NK/T-cell lymphoma, nasal type and aggressive NK-cell leukemia.
  • Lymphoma cells are characteristically CD2+, CD56+ and cytoplasmic CD3epsilon+.
  • Clinically, they can be divided into nasal, non-nasal, and aggressive lymphoma/leukemia subtypes.
  • Chemotherapy is indicated for advanced nasal NK-cell lymphoma, and the non-nasal and aggressive subtypes.
  • [MeSH-major] Killer Cells, Natural / pathology. Leukemia. Lymphoma

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16179910.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 83
  •  go-up   go-down


33. Booken N, Gratchev A, Utikal J, Weiss C, Yu X, Qadoumi M, Schmuth M, Sepp N, Nashan D, Rass K, Tüting T, Assaf C, Dippel E, Stadler R, Klemke CD, Goerdt S: Sézary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3. Leukemia; 2008 Feb;22(2):393-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sézary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3.
  • Sezary syndrome (SS) is a rare, aggressive CD4+ cutaneous T-cell lymphoma (CTCL); molecular traits differentiating SS from nonleukemic mycosis fungoides (MF) and from inflammatory skin diseases (ID) are not sufficiently characterized.
  • [MeSH-major] Cysteine Dioxygenase / genetics. Dynamin III / genetics. Lymphoma, T-Cell, Cutaneous / genetics. Sezary Syndrome / genetics

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • Genetic Alliance. consumer health - Sezary syndrome.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18033314.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; EC 1.13.11.20 / Cysteine Dioxygenase; EC 3.6.5.5 / Dynamin III
  •  go-up   go-down


34. Paydas S, Seydaoglu G, Ergin M, Erdogan S, Yavuz S: The prognostic significance of VEGF-C and VEGF-A in non-Hodgkin lymphomas. Leuk Lymphoma; 2009 Mar;50(3):366-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic significance of VEGF-C and VEGF-A in non-Hodgkin lymphomas.
  • The aim of this study is to determine the prognostic role of angiogenesis and lymphangiogenesis in the development of lymphoma.
  • The OS was significantly shorter in aggressive lymphomas expressing VEGF-A and VEGF-C but not in indolent lymphomas.
  • In conclusion, VEGF-C and VEGF-A were positive in 34 and 61%, respectively, of the cases with NHL.
  • Autocrine VEGF-A and VEGF-C crosstalks in lymphoma cells are important in lymphoma biology and inhibition of these signals with anti-angiogenic/anti-lymphangiogenic drugs and combination with chemo-immunotherapy regimens will be more useful in these cases.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Vascular Endothelial Growth Factor A / analysis. Vascular Endothelial Growth Factor C / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2009 Mar;50(3):311-2 [19347719.001]
  • (PMID = 19347725.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factor C
  •  go-up   go-down


35. He H, Cheng L, Weiss LM, Chu PG: Clinical outcome of incidental pelvic node malignant B-cell lymphomas discovered at the time of radical prostatectomy. Leuk Lymphoma; 2007 Oct;48(10):1976-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of 13 cases, 9 were chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), 3 marginal zone B-cell lymphoma (MZL) and 1 mantle cell lymphoma (MCL).
  • All 13 patients did not receive radiation or chemotherapy; and five of 13 cases showed hematologic evidence of lymphoma progression between 1 and 5 months after radical prostatectomy.
  • After progression, the mantle cell lymphoma patient received aggressive chemotherapy and had systemic dissemination.
  • None of 13 patients had died from lymphoma or prostate carcinoma at the last follow-up.
  • Strong consideration should be given to withholding further treatment in patients diagnosed with pelvic low-grade B-cell lymphoma at the time of radical prostatectomy until disease progression occurs.
  • [MeSH-major] Lymphoma, B-Cell / immunology. Lymphoma, B-Cell / therapy. Neoplasms, Second Primary / therapy. Prostatic Neoplasms / surgery. Prostatic Neoplasms / therapy

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17917966.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


36. Batlle M, Ribera JM, Oriol A, Pastor C, Mate JL, Fernández-Avilés F, Flores A, Millá F, Feliu E: Usefulness of tumor markers CA 125 and CA 15.3 at diagnosis and during follow-up in non-Hodgkin's lymphoma: study of 200 patients. Leuk Lymphoma; 2005 Oct;46(10):1471-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of tumor markers CA 125 and CA 15.3 at diagnosis and during follow-up in non-Hodgkin's lymphoma: study of 200 patients.
  • CA 125 and CA 15.3 serum levels were measured at diagnosis, after treatment and at the time of recurrence in 200 consecutive patients (114 males, median age 56 years) with non-Hodgkin's lymphoma (NHL) to explore its usefulness in the evaluation of response to treatment and survival in patients with NHL compared to lactate dehydrogense (LDH) and beta2-microglobulin (beta2-M).
  • CA 125 was associated with advanced stage, lung, pleural or gastrointestinal tract involvement and CA 15.3 was correlated with advanced stage, bone involvement, aggressive histology and bulky disease.
  • When elevated at diagnosis, CA 125 and CA 15.3 should be monitored during follow-up of patients with NHL.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Lymphoma, Non-Hodgkin / blood. Lymphoma, Non-Hodgkin / diagnosis. Mucin-1 / blood

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16194893.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Mucin-1
  •  go-up   go-down


37. Gladney SP, Lonial S, Kaufman JL: Multiple myeloma presenting with advanced renal failure: a case report and new treatment options. Clin Lymphoma Myeloma; 2008 Feb;8(1):52-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Herein, we report on a patient who presented with aggressive myeloma and severe renal failure requiring hemodialysis.
  • We review the data on treatment approaches for patients with renal failure and focus on the use of aggressive induction therapy with novel therapeutics.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18501088.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Pyrazines; 4Z8R6ORS6L / Thalidomide; 69G8BD63PP / Bortezomib; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


38. Callens C, Moura IC, Lepelletier Y, Coulon S, Renand A, Dussiot M, Ghez D, Benhamou M, Monteiro RC, Bazarbachi A, Hermine O: Recent advances in adult T-cell leukemia therapy: focus on a new anti-transferrin receptor monoclonal antibody. Leukemia; 2008 Jan;22(1):42-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HTLV-I is an endemic retrovirus responsible for the adult T-cell leukemia/lymphoma (ATLL).
  • This aggressive lymphoid proliferation is associated with a bad prognosis due to the resistance of HTLV-I-infected cells to most classical chemotherapeutic agents.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17898788.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Receptors, Transferrin
  • [Number-of-references] 53
  •  go-up   go-down


39. Rossi JG, Felice MS, Bernasconi AR, Ribas AE, Gallego MS, Somardzic AE, Alfaro EM, Alonso CN: Acute leukemia of dendritic cell lineage in childhood: incidence, biological characteristics and outcome. Leuk Lymphoma; 2006 Apr;47(4):715-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The few cases described, mostly adults and elderly, typically present with cutaneous lesions, followed by disseminated tumor localizations within a few months, with a generally very aggressive course and fatal outcome, despite the different therapeutic approaches employing chemotherapy and/or radiotherapy.
  • These findings, in spite of the small number of patients, suggest that the clinical course in children might be less aggressive, and that regular ALL protocols would be effective.
  • [MeSH-major] Dendritic Cells / cytology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16690531.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


40. Eros N, Marschalkó M, Balassa K, Hídvégi B, Szakonyi J, Ilniczky S, Borka K, Kovács A, Bottlik G, Hársing J, Csomor J, Szepesi A, Matolcsy A, Kárpáti S, Demeter J: Central nervous system involvement in CD4+/CD56+ hematodermic neoplasm: a report of two cases. J Neurooncol; 2010 Apr;97(2):301-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CD4+/CD56+ hematodermic neoplasm, formerly known as blastic NK-cell lymphoma, is an uncommon, aggressive non-Hodgkin's lymphoma with cutaneous, lymph node, and bone marrow involvement at presentation.
  • Authors recommend routine cerebrospinal fluid analysis and prophylactic intrathecal chemotherapy in patients with this highly aggressive disease.
  • [MeSH-major] Lymphoma, Extranodal NK-T-Cell / pathology. Lymphoma, Extranodal NK-T-Cell / physiopathology. Meningeal Neoplasms / pathology. Meningeal Neoplasms / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2005 Sep;36(9):1020-4 [16153467.001]
  • [Cites] Dermatology. 2000;200(3):202-8 [10828627.001]
  • [Cites] Haematologica. 2006 Jan;91(1):143-4 [16434387.001]
  • [Cites] Am J Clin Pathol. 2002 Jan;117(1):41-50 [11789729.001]
  • [Cites] J Am Acad Dermatol. 2001 Feb;44(2):231-8 [11174380.001]
  • [Cites] Am J Clin Pathol. 1998 Oct;110(4):478-88 [9763034.001]
  • [Cites] Am J Surg Pathol. 1999 Feb;23(2):137-46 [9989839.001]
  • [Cites] Mod Pathol. 2006 Dec;19(12):1555-62 [16998465.001]
  • [Cites] Am J Hematol. 1994 Dec;47(4):278-82 [7526680.001]
  • [Cites] Ann Oncol. 2004 Jul;15(7):1097-108 [15205205.001]
  • [Cites] J Am Acad Dermatol. 2008 Mar;58(3):480-4 [18280345.001]
  • [Cites] Am J Hematol. 2003 Sep;74(1):46-51 [12949889.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):662-75 [15981806.001]
  • [Cites] Haematologica. 2006 Dec;91(12 Suppl):ECR48 [17194654.001]
  • (PMID = 19798469.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Antineoplastic Agents
  •  go-up   go-down


41. Gopal AK, Pagel JM, Rajendran JG, Maloney DG, Appelbaum FR, Sorror ML, Sandmaier BM, Storb R, Press OW: Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy. Biol Blood Marrow Transplant; 2006 Jul;12(7):697-702
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy.
  • Nonmyeloablative allogeneic transplantation provides a valuable therapeutic option for patients with relapsed non-Hodgkin lymphomas, particularly those that have recurred after autologous transplantation.
  • However, the absence of an intensive conditioning regimen renders this approach less effective for patients with aggressive or bulky lymphoma because rapid tumor growth may outpace the evolution of the graft-versus-lymphoma effect.
  • This approach provides a time window during which a robust graft-versus-lymphoma effect may be established before tumor progression, thereby providing more effective long-term disease control.
  • The rationale for incorporation of radioimmunotherapy into reduced intensity allogeneic transplantation regimens for non-Hodgkin lymphoma is discussed, as are current study designs, preliminary results, and future directions.

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16785058.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA078902; United States / NCI NIH HHS / CA / CA15704; United States / NCI NIH HHS / CA / CA18029; United States / NCI NIH HHS / CA / CA78902
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / iodine-131 anti-B1 antibody
  • [Number-of-references] 34
  •  go-up   go-down


42. Mihara K, Yanagihara K, Takigahira M, Kitanaka A, Imai C, Bhattacharyya J, Kubo T, Takei Y, Yasunaga S, Takihara Y, Kimura A: Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma. Br J Haematol; 2010 Oct;151(1):37-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
  • Given that B-cell non-Hodgkin lymphoma (B-NHL) cells invariably express CD19 and CD38, these antigens may be suitable molecular candidates for such immunotherapy.
  • The T cell line, Hut78, when transduced with anti-CD19-CAR or anti-CD38-CAR, exerted strong cytotoxicity against the B-NHL cell lines, HT and RL, and lymphoma cells isolated from patients.
  • These results provide a powerful rationale for clinical testing of the combination of rituximab with autologous T cells carrying either CAR on aggressive or relapsed B-NHLs.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / therapy. Receptors, Antigen / immunology. T-Lymphocytes / transplantation

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Ltd.
  • (PMID = 20678160.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD19; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / Membrane Glycoproteins; 0 / Receptors, Antigen; 4F4X42SYQ6 / Rituximab; EC 3.2.2.5 / Antigens, CD38; EC 3.2.2.5 / CD38 protein, human
  •  go-up   go-down


43. Takasaki Y, Iwanaga M, Tsukasaki K, Kusano M, Sugahara K, Yamada Y, Kamihira S, Ikeda S, Tomonaga M: Impact of visceral involvements and blood cell count abnormalities on survival in adult T-cell leukemia/lymphoma (ATLL). Leuk Res; 2007 Jun;31(6):751-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of visceral involvements and blood cell count abnormalities on survival in adult T-cell leukemia/lymphoma (ATLL).
  • Multiple visceral involvements and various blood cell count abnormalities are frequently manifested in adult T-cell leukemia/lymphoma (ATLL) at diagnosis.
  • In the aggressive type, BM involvement, skin involvement and monocytosis were significantly poor prognostic factors.
  • [MeSH-major] Anemia / pathology. Bone Marrow / pathology. Leukemia-Lymphoma, Adult T-Cell / pathology. Leukocyte Disorders / pathology

  • MedlinePlus Health Information. consumer health - Anemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17188352.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  •  go-up   go-down


44. Shimoni A, Nagler A: Radioimmunotherapy and stem-cell transplantation in the treatment of aggressive B-cell lymphoma. Leuk Lymphoma; 2007 Nov;48(11):2110-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radioimmunotherapy and stem-cell transplantation in the treatment of aggressive B-cell lymphoma.
  • High-dose chemotherapy and autologous stem-cell transplantation (ASCT) have an established therapeutic role in the treatment of chemo-sensitive relapsed aggressive lymphoma, but has limited success in chemo-refractory disease or in heavily pretreated, multiple relapsed patients.
  • Methods for better eradication of underlying lymphoma are needed to improve outcome.
  • Two radioimmunoconjugates are currently approved for relapsed/resistant low-grade or transformed lymphoma: iodine-131 tositumomab and yttrium-90 ibritumomab tiuxetan.
  • These agents are also effective in aggressive lymphoma.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, B-Cell / therapy. Radioimmunotherapy

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17891639.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 59
  •  go-up   go-down


45. Rodig SJ, Payne EG, Degar BA, Rollins B, Feldman AL, Jaffe ES, Androkites A, Silverman LB, Longtine JA, Kutok JL, Fleming MD, Aster JC: Aggressive Langerhans cell histiocytosis following T-ALL: clonally related neoplasms with persistent expression of constitutively active NOTCH1. Am J Hematol; 2008 Feb;83(2):116-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive Langerhans cell histiocytosis following T-ALL: clonally related neoplasms with persistent expression of constitutively active NOTCH1.
  • Analysis of cDNA prepared from the aggressive Langerhans cell tumor showed that the NOTCH1 mutations were aligned in cis, a configuration that caused synergistic increases in NOTCH1 signal strength in reporter gene assays.
  • Thus, activating NOTCH1 mutations appear to be unique to aggressive Langerhans cell tumors occurring after T-ALL.

  • Genetic Alliance. consumer health - Histiocytosis.
  • Genetic Alliance. consumer health - Langerhans cell histiocytosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17874453.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / AI050225; United States / NCI NIH HHS / CA / CA082308; United States / NCI NIH HHS / CA / CA119070-02; United States / NCI NIH HHS / CA / P01 CA119070-02; United States / NCI NIH HHS / CA / P01 CA119070
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NOTCH1 protein, human; 0 / Receptor, Notch1
  •  go-up   go-down


46. Strömberg S, Agnarsdóttir M, Magnusson K, Rexhepaj E, Bolander A, Lundberg E, Asplund A, Ryan D, Rafferty M, Gallagher WM, Uhlen M, Bergqvist M, Ponten F: Selective expression of Syntaxin-7 protein in benign melanocytes and malignant melanoma. J Proteome Res; 2009 Apr;8(4):1639-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In tumor tissues, STX7 was expressed in malignant melanoma and lymphoma.
  • The expression level of STX7 protein was inversely correlated to tumor stage, suggesting that decreased expression of STX7 is associated with more aggressive tumors.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19714869.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Qa-SNARE Proteins
  •  go-up   go-down


47. Huang Z, Higgins B, Foss F: Activity of gallium nitrate in refractory peripheral T-cell lymphoma. Clin Lymphoma; 2005 Jun;6(1):43-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity of gallium nitrate in refractory peripheral T-cell lymphoma.
  • Peripheral T-cell lymphomas (PTCLs) are post-thymic malignancies characterized by an aggressive clinical course and an inferior outcome with standard therapies.
  • [MeSH-major] Gallium / therapeutic use. Lymphoma, T-Cell / drug therapy

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Hazardous Substances Data Bank. GALLIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15989706.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 13494-90-1 / gallium nitrate; CH46OC8YV4 / Gallium
  •  go-up   go-down


48. Quintás-Cardama A, Amin HM, Kantarjian H, Verstovsek S: Treatment of aggressive systemic mastocytosis with daclizumab. Leuk Lymphoma; 2010 Mar;51(3):540-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of aggressive systemic mastocytosis with daclizumab.

  • Genetic Alliance. consumer health - Aggressive Systemic Mastocytosis.
  • Genetic Alliance. consumer health - Mast cell disease.
  • Genetic Alliance. consumer health - Systemic mastocytosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038223.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Immunoglobulin G; CUJ2MVI71Y / daclizumab
  •  go-up   go-down


49. Moreira JN, Santos A, Simões S: Bcl-2-targeted antisense therapy (Oblimersen sodium): towards clinical reality. Rev Recent Clin Trials; 2006 Sep;1(3):217-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bcl-2 is an anti-apoptotic protein, whose overexpression is associated with chemotherapy resistant cancer, aggressive clinical course and poor survival.
  • [MeSH-minor] Breast Neoplasms. Carcinoma, Small Cell / drug therapy. Clinical Trials as Topic. Colorectal Neoplasms / secondary. Down-Regulation / drug effects. Drug Therapy, Combination. Female. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Myeloid, Acute / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Male. Melanoma / drug therapy. Prostatic Neoplasms / drug therapy. Proto-Oncogene Proteins c-bcl-2 / metabolism

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18473975.001).
  • [ISSN] 1574-8871
  • [Journal-full-title] Reviews on recent clinical trials
  • [ISO-abbreviation] Rev Recent Clin Trials
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Oligonucleotides, Antisense; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Thionucleotides; 85J5ZP6YSL / oblimersen
  • [Number-of-references] 86
  •  go-up   go-down


50. Galligan L, Catherwood MA, Matthews C, Morris TC, Alexander HD: Mutated IgHV1-69 gene usage represents a distinct subgroup associated with indolent disease in chronic lymphocytic leukemia. Leuk Lymphoma; 2008 Apr;49(4):763-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, we show that a somatically hypermutated subgroup may demonstrate more indolent characteristics despite the general association of IgHV1-69 gene usage with aggressive disease.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2008 Apr;49(4):648-9 [18398727.001]
  • (PMID = 18398745.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Complementarity Determining Regions; 0 / Immunoglobulin Heavy Chains; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


51. Dunleavy K, Piekarz RL, Zain J, Janik JE, Wilson WH, O'Connor OA, Bates SE: New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies. Clin Cancer Res; 2010 Dec 1;16(23):5608-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies.
  • Peripheral T-cell lymphomas (PTCL) constitute a group of heterogeneous diseases that are uncommon, representing, in Western countries, only approximately 10% of all non-Hodgkin lymphomas.
  • Although the outcome for patients with anaplastic large cell lymphoma (ALCL), particularly anaplastic lymphoma kinase (ALK)-positive ALCL, is good, other types of PTCLs are associated with a poor prognosis, even with aggressive anthracycline-based chemotherapy.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / diagnosis. Lymphoma, T-Cell, Peripheral / etiology. Lymphoma, T-Cell, Peripheral / therapy. Therapies, Investigational / trends

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Leukemia. 2005 Dec;19(12):2254-63 [16270046.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):924-32 [16467107.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Mar;3(3):165-8; quiz 169 [16520806.001]
  • [Cites] Am J Surg Pathol. 2006 Apr;30(4):490-4 [16625095.001]
  • [Cites] Clin Cancer Res. 2006 Jun 15;12(12):3762-73 [16778104.001]
  • [Cites] Blood. 2006 Jul 15;108(2):705-10 [16551968.001]
  • [Cites] Br J Haematol. 2007 Feb;136(3):439-47 [17233846.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):746-55 [17234786.001]
  • [Cites] J Clin Invest. 2007 Mar;117(3):823-34 [17304354.001]
  • [Cites] Ann Oncol. 2007 Apr;18(4):652-7 [17229774.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Jun;60(1):129-34 [17406867.001]
  • [Cites] Leuk Lymphoma. 2007 Mar;48(3):521-5 [17454592.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4952-63 [17284527.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4655-62 [17311990.001]
  • [Cites] Oncogene. 2007 May 28;26(25):3699-703 [17530023.001]
  • [Cites] Curr Opin Hematol. 2007 Jul;14(4):348-53 [17534160.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):2764-9 [17515574.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3109-15 [17577020.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4293-7 [17709797.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2316-23 [17581918.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1848-54 [18079362.001]
  • [Cites] J Clin Oncol. 2008 May 10;26(14):2264-71 [18390969.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jul;14(7):741-7 [18541192.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1139-43 [18401419.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4500-10 [18628465.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4124-30 [18626005.001]
  • [Cites] Leuk Lymphoma. 2008 Sep;49(9):1836-8 [18661402.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4952-7 [18606983.001]
  • [Cites] Ann Oncol. 2008 Dec;19(12):2079-83 [18689866.001]
  • [Cites] Bone Marrow Transplant. 2008 Dec;42(12):773-81 [18936735.001]
  • [Cites] Clin Cancer Res. 2009 Apr 1;15(7):2514-22 [19293260.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3509-15 [10552961.001]
  • [Cites] Br J Cancer. 2000 Sep;83(6):817-25 [10952788.001]
  • [Cites] Mol Cell. 2000 Aug;6(2):395-407 [10983986.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4307-12 [11110706.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):376-88 [11208829.001]
  • [Cites] Br J Haematol. 2001 Apr;113(1):185-7 [11328299.001]
  • [Cites] J Clin Oncol. 2001 Sep 1;19(17):3766-70 [11533100.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2865-8 [11675364.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):718-28 [11895901.001]
  • [Cites] Med Oncol. 2002;19 Suppl:S27-32 [12180489.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2609-17 [12826635.001]
  • [Cites] Leuk Lymphoma. 2003 Jun;44(6):1027-35 [12854905.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2744-54 [12855655.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3737-42 [12881320.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):342-9 [14716770.001]
  • [Cites] Br J Haematol. 2009 May;145(3):344-9 [19245430.001]
  • [Cites] Clin Cancer Res. 2009 Jun 15;15(12):3918-26 [19509169.001]
  • [Cites] Br J Haematol. 2009 Jul;146(2):171-9 [19466965.001]
  • [Cites] J Clin Oncol. 2009 Sep 10;27(26):4357-64 [19652067.001]
  • [Cites] Am J Health Syst Pharm. 2009 Nov 1;66(21):1890 [19850775.001]
  • [Cites] J Clin Oncol. 2009 Nov 10;27(32):5410-7 [19826128.001]
  • [Cites] Leukemia. 2010 Jan;24(1):229-32 [19776763.001]
  • [Cites] Br J Haematol. 2010 Jan;148(2):256-67 [19874311.001]
  • [Cites] Blood. 2010 Feb 4;115(5):1026-36 [19965671.001]
  • [Cites] Leuk Lymphoma. 2010 Mar;51(3):447-55 [20141439.001]
  • [Cites] J Clin Oncol. 2010 Mar 20;28(9):1591-8 [20177026.001]
  • [Cites] Ann Oncol. 2010 Apr;21(4):860-3 [19887465.001]
  • [Cites] Blood. 2010 Apr 1;115(13):2578-85 [19965662.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2920-4 [15070664.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1952-60 [15213097.001]
  • [Cites] Leuk Res. 2004 Dec;28(12):1287-92 [15475070.001]
  • [Cites] Leuk Lymphoma. 2004 Nov;45(11):2261-7 [15512815.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jan;86(2):602-6 [2783489.001]
  • [Cites] Cell. 1992 Feb 7;68(3):421-7 [1310894.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5335-41 [7585597.001]
  • [Cites] Blood. 1996 Jan 1;87(1):284-91 [8547653.001]
  • [Cites] Mol Cell Biol. 1997 Apr;17(4):2312-25 [9121481.001]
  • [Cites] Leukemia. 1997 Aug;11(8):1367-72 [9264394.001]
  • [Cites] Blood. 1998 Jan 15;91(2):399-405 [9427692.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6791-6 [9618491.001]
  • [Cites] Ann Oncol. 1998 Dec;9(12):1351-3 [9932168.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2697-706 [10194450.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):667-75 [15613697.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):676-84 [15613699.001]
  • (PMID = 21138864.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS236831; NLM/ PMC3058794
  •  go-up   go-down


52. Castillo J, Pantanowitz L, Dezube BJ: HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol; 2008 Oct;83(10):804-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases.
  • Plasmablastic lymphoma (PBL) is a distinct subtype of non-Hodgkin B-cell lymphoma, originally described with a strong predilection to the oral cavity of human immunodeficiency virus (HIV)-infected individuals.
  • PBL is an aggressive B-cell lymphoma that presents in both oral and extra-oral sites of chronically HIV-infected immunosuppressed young men.
  • [MeSH-major] Lymphoma, Large-Cell, Immunoblastic / complications
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active / methods. CD4 Lymphocyte Count. Combined Modality Therapy / statistics & numerical data. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Herpesvirus 4, Human / isolation & purification. Humans. Lymphoma, AIDS-Related / epidemiology. Lymphoma, AIDS-Related / mortality. Lymphoma, AIDS-Related / therapy. Prednisone / therapeutic use. Survival Analysis. Vincristine / therapeutic use. Viral Load

  • Genetic Alliance. consumer health - HIV.
  • HIV InSite. treatment guidelines - Pneumocystosis and HIV .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 Wiley-Liss, Inc.
  • [CommentIn] Am J Hematol. 2008 Oct;83(10):763-4 [18756546.001]
  • (PMID = 18756521.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 51
  •  go-up   go-down


53. Tomita N, Tokunaka M, Nakamura N, Takeuchi K, Koike J, Motomura S, Miyamoto K, Kikuchi A, Hyo R, Yakushijin Y, Masaki Y, Fujii S, Hayashi T, Ishigatsubo Y, Miura I: Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. Haematologica; 2009 Jul;94(7):935-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations.
  • BACKGROUND: Lymphoid neoplasm with 18q21.3/BCL2 and 8q24/MYC translocation to immunoglobulin (IG) genes as dual-hit lymphoma/leukemia is very rare and known to have a poor clinical outcome.
  • DESIGN AND METHODS: To clarify the clinicopathological characteristics of this malignancy, we analyzed 27 cases of cytogenetically proven dual-hit lymphoma/leukemia.
  • RESULTS: Dual-hit lymphoma/leukemia was diagnosed at presentation in 22 cases and at relapse or disease progression in 5 cases.
  • At the time of diagnosis of dual-hit lymphoma/leukemia, extranodal involvement was found in 25 cases (93%) and central nervous system involvement occurred in 15 cases (56%).
  • The median survival and 1-year survival rate of the 27 cases were only 6 months and 22%, respectively, after diagnosis of the dual-hit lymphoma/leukemia.
  • Seven cases of triple-hit lymphoma/leukemia (dual-hit lymphoma/leukemia with 3q27/BCL6 translocation) were included; the median survival of these patients was only 4 months from the diagnosis of the dual-hit lymphoma/leukemia.
  • The duration of survival of the patients with a triple-hit malignancy was shorter than that of the other 20 cases of dual-hit lymphoma/leukemia (p=0.02).
  • The MIB-1 index was investigated in 14 cases with aggressive B-cell lymphoma, and was higher in the group with MYC-IGH translocation (n=7) than in the MYC-IGK/L group (n=7) (p=0.02).
  • CONCLUSIONS: Dual-hit lymphoma/leukemia is a rare but distinct mature B-cell neoplasm with an extremely poor prognosis characterized by frequent extranodal involvement and central nervous system progression with either of the translocation partners of MYC.
  • [MeSH-major] Genes, bcl-2. Genes, myc. Leukemia / diagnosis. Leukemia / genetics. Lymphoma / diagnosis. Lymphoma / genetics. Translocation, Genetic


54. Landsmann S, Todorov J, v Streitberg U, Seitz G, Weingärtner K: [Plasmocytoma of the ureter--a rare cause of hydronephrosis: case report and review of the literature]. Aktuelle Urol; 2009 May;40(3):175-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Plasmocytoma is an aggressive B-cell lymphoma with diffuse and multi-located-infiltration of the bone marrow.

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19370534.001).
  • [ISSN] 1438-8820
  • [Journal-full-title] Aktuelle Urologie
  • [ISO-abbreviation] Aktuelle Urol
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 7
  •  go-up   go-down


55. Brepoels L, Stroobants S, De Wever W, Spaepen K, Vandenberghe P, Thomas J, Uyttebroeck A, Mortelmans L, De Wolf-Peeters C, Verhoef G: Aggressive and indolent non-Hodgkin's lymphoma: response assessment by integrated international workshop criteria. Leuk Lymphoma; 2007 Aug;48(8):1522-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive and indolent non-Hodgkin's lymphoma: response assessment by integrated international workshop criteria.
  • Until recently, response assessment in patients with lymphoma was primarily performed by computed tomography (CT).
  • Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) is a more sensitive and specific imaging technique for the detection of residual disease in lymphoma, and Revised Integrated International Workshop Criteria (IWC + PET) were recently proposed by the members of the International Harmonization Project (IHP), which combine both imaging techniques.
  • We determined whether these new IWC + PET-criteria, can more accurately predict outcome compared to IWC-criteria in aggressive and indolent non-Hodgkin's lymphoma (NHL), and therefore correlated IWC and IWC + PET response with time-to-next-treatment (TNT) in 69 patients with NHL.
  • We demonstrated that IWC + PET-guidelines are highly recommended over IWC-guidelines for patients with potentially-curable and routinely FDG-avid lymphoma.
  • [MeSH-major] Fluorodeoxyglucose F18. Lymphoma, Non-Hodgkin / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals
  • [MeSH-minor] Adolescent. Adult. Aged. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / radiography. Burkitt Lymphoma / radionuclide imaging. Humans. International Cooperation. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / radiography. Lymphoma, B-Cell / radionuclide imaging. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / radiography. Lymphoma, Large B-Cell, Diffuse / radionuclide imaging. Middle Aged. Neoplasm Recurrence, Local / etiology. Neoplasm Recurrence, Local / pathology. Neoplasms, Second Primary / etiology. Neoplasms, Second Primary / pathology. Practice Guidelines as Topic. Predictive Value of Tests. Sensitivity and Specificity. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17701583.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


56. Alduaij A, Butera JN, Treaba D, Castillo J: Complete remission in two cases of adult T-cell leukemia/lymphoma treated with hyper-CVAD: a case report and review of the literature. Clin Lymphoma Myeloma Leuk; 2010 Dec;10(6):480-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission in two cases of adult T-cell leukemia/lymphoma treated with hyper-CVAD: a case report and review of the literature.
  • BACKGROUND: Acute T-cell leukemia/lymphoma (ATLL) is a post thymic (peripheral) T-cell neoplasm caused by human T-cell lymphotropic virus type 1 (HTLV-1).
  • However, its prognosis is poor and median survival in the aggressive variants of ATLL is only 6-10 months.
  • Recently, a more aggressive regimen piloted in Japan, vincristine/cyclophosphamide/doxorubicin/prednisone (VCAP)- doxorubicin/ranimustine/prednisone (AMP)- vindesine/etoposide/carboplatin/prednisone (VECP), has been reported to yield better survival results over biweekly CHOP in a phase III trial.
  • However, the hyper- cyclophosphamide/vincristine/doxorubicin/dexamethasone (CVAD) regimen is a much more frequently used regimen for the treatment of aggressive hematologic malignancies, and has a higher intensity then CHOP.
  • CONCLUSION: A commonly used chemotherapy regimen for aggressive hematologic malignancies, hyper-CVAD, can induce durable remissions in patients with ATLL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21156467.001).
  • [ISSN] 2152-2669
  • [Journal-full-title] Clinical lymphoma, myeloma & leukemia
  • [ISO-abbreviation] Clin Lymphoma Myeloma Leuk
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


57. Yu Z, Loehr CV, Fischer KA, Louderback MA, Krueger SK, Dashwood RH, Kerkvliet NI, Pereira CB, Jennings-Gee JE, Dance ST, Miller MS, Bailey GS, Williams DE: In utero exposure of mice to dibenzo[a,l]pyrene produces lymphoma in the offspring: role of the aryl hydrocarbon receptor. Cancer Res; 2006 Jan 15;66(2):755-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In utero exposure of mice to dibenzo[a,l]pyrene produces lymphoma in the offspring: role of the aryl hydrocarbon receptor.
  • Lymphoma and leukemia are the most common cancers in children and young adults; in utero carcinogen exposure may contribute to the etiology of these cancers.
  • Significant mortalities in offspring, beginning at 12 weeks of age, were observed due to an aggressive T-cell lymphoblastic lymphoma.
  • Offspring born to nonresponsive mothers had greater susceptibility to lymphoma, irrespective of offspring phenotype.
  • This is the first demonstration that transplacental exposure to an environmental PAH can induce a highly aggressive lymphoma in mice and raises the possibility that PAH exposures to pregnant women could contribute to similar cancers in children and young adults.

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DIBENZO(A,L)PYRENE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16424006.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 90890; United States / NIEHS NIH HHS / ES / ES 03850; United States / NIEHS NIH HHS / ES / ES 00210; United States / NCI NIH HHS / CA / CA 80176; United States / NIEHS NIH HHS / ES / P42 ES016465; United States / NCI NIH HHS / CA / CA 91909; United States / NIEHS NIH HHS / ES / P30 ES000210
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzopyrenes; 0 / Carcinogens; 0 / Receptors, Aryl Hydrocarbon; 191-30-0 / dibenzo(a,l)pyrene
  •  go-up   go-down


58. Hoang B, Zhu L, Shi Y, Frost P, Yan H, Sharma S, Sharma S, Goodglick L, Dubinett S, Lichtenstein A: Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance. Blood; 2006 Jun 1;107(11):4484-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oncogenic RAS expression occurs in up to 40% of multiple myeloma (MM) cases and correlates with aggressive disease.
  • We used cox-2 inhibitors, NS398 and celecoxib, and neutralizing anti-PGE2 antibody to test whether cox-2/PGE2 was involved in the aggressive phenotype of MM ANBL-6 cells containing mutated RAS.

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FASEB J. 2004 Jan;18(1):206-8 [14597555.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3126-35 [12515720.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 May;82(10):3477-80 [3858834.001]
  • [Cites] J Exp Med. 1989 Nov 1;170(5):1715-25 [2681517.001]
  • [Cites] Oncogene. 1990 Nov;5(11):1659-63 [2267133.001]
  • [Cites] J Cell Biol. 1992 Feb;116(3):817-25 [1730778.001]
  • [Cites] Oncogene. 1992 Dec;7(12):2539-43 [1461658.001]
  • [Cites] Blood. 1993 May 15;81(10):2708-13 [8490179.001]
  • [Cites] Cancer Res. 1995 Aug 15;55(16):3640-6 [7627974.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2699-706 [8839865.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):930-6 [9041197.001]
  • [Cites] Endocrinology. 1997 Jun;138(6):2372-9 [9165025.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2268-75 [9187131.001]
  • [Cites] Stroke. 1998 Jun;29(6):1219-22 [9626297.001]
  • [Cites] J Biol Chem. 1998 Aug 21;273(34):22120-7 [9705357.001]
  • [Cites] Blood. 1999 Mar 1;93(5):1658-67 [10029595.001]
  • [Cites] Leuk Lymphoma. 2005 Mar;46(3):425-33 [15621834.001]
  • [Cites] Cancer Sci. 2005 Feb;96(2):93-9 [15723653.001]
  • [Cites] Int J Cancer. 2005 Jun 20;115(3):484-92 [15688368.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4784-91 [15731178.001]
  • [Cites] Int J Cancer. 2005 Sep 10;116(4):536-46 [15825163.001]
  • [Cites] Biochem Pharmacol. 2005 Sep 1;70(5):658-67 [16004971.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5504-14 [16061867.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1240-5 [15860667.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Oct;90(10):5754-60 [16091477.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4330-8 [16123214.001]
  • [Cites] Int J Cancer. 1997 May 2;71(3):364-9 [9139869.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1953-60 [10961900.001]
  • [Cites] Blood. 2000 Nov 1;96(9):3175-80 [11050000.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2670-5 [11289146.001]
  • [Cites] J Biol Chem. 2001 Jun 15;276(24):20809-12 [11320076.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1555-60 [11520807.001]
  • [Cites] Leukemia. 2002 Jan;16(1):135-43 [11840273.001]
  • [Cites] J Biol Chem. 2002 Nov 29;277(48):45838-46 [12237321.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):961-8 [12631593.001]
  • [Cites] Cancer Cell. 2004 Feb;5(2):191-9 [14998494.001]
  • (PMID = 16497971.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 111448; United States / NCI NIH HHS / CA / CA 111851; United States / NCI NIH HHS / CA / CA 96920; United States / NCI NIH HHS / CA / CA-86366
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fibronectins; EC 1.14.99.1 / Cyclooxygenase 2; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras); K7Q1JQR04M / Dinoprostone
  • [Other-IDs] NLM/ PMC1895799
  •  go-up   go-down


59. Palmieri C, Falcone C, Iaccino E, Tuccillo FM, Gaspari M, Trimboli F, De Laurentiis A, Luberto L, Pontoriero M, Pisano A, Vecchio E, Fierro O, Panico MR, Larobina M, Gargiulo S, Costa N, Dal Piaz F, Schiavone M, Arra C, Giudice A, Palma G, Barbieri A, Quinto I, Scala G: In vivo targeting and growth inhibition of the A20 murine B-cell lymphoma by an idiotype-specific peptide binder. Blood; 2010 Jul 15;116(2):226-38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo targeting and growth inhibition of the A20 murine B-cell lymphoma by an idiotype-specific peptide binder.
  • B-cell lymphoma is a clonal expansion of neoplastic cells that may result in fatal outcomes.
  • Here, we report the in vivo targeting and growth inhibition of aggressive A20 murine B-cell lymphoma by idiotype-specific peptide pA20-36. pA20-36 was selected from random peptide libraries and bound specifically to the B-cell receptor (BCR) of A20 cells in mice engrafted with A20 lymphoma, as shown by histology and positron emission tomographic analysis.
  • [MeSH-major] Antibodies, Anti-Idiotypic / immunology. Immunotherapy / methods. Lymphoma, B-Cell / immunology. Peptides / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20363775.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Anti-Idiotypic; 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Immunoglobulin Idiotypes; 0 / Peptide Library; 0 / Peptides; 0 / Receptors, Antigen, B-Cell
  •  go-up   go-down


60. Weidmann E, Hess G, Chow KU, Krause SW, Subklewe M, Kruse J, Weisel KC, Soekler M, Kim SZ, Napieralski S, Rech J, Dreyling M, Jäger E, Mitrou PS: A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas. Leuk Lymphoma; 2010 Mar;51(3):447-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinical course of peripheral T-cell lymphoma (PTCL) is usually aggressive and the prognosis unfavorable.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antibodies, Neoplasm / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Lymphoma, T-Cell / drug therapy. Vidarabine / analogs & derivatives

  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20141439.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 3A189DH42V / alemtuzumab; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


61. Yu JH, Choi KD, Koh YW, Choi WJ, Song HJ, Lee GH, Jung HY, Kim JH: [A case of CD56+ extranodal NK/T-cell lymphoma, nasal type, presenting as a duodenal ulcer bleeding]. Korean J Gastroenterol; 2009 Sep;54(3):174-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of CD56+ extranodal NK/T-cell lymphoma, nasal type, presenting as a duodenal ulcer bleeding].
  • Extranodal NK/T-cell lymphoma is a recently recognized distinct entity within the World Health Organization classification of lymphoid tumors.
  • Among these, extranodal NK/T-cell lymphoma of the gastrointestinal tract has shown an aggressive clinical course.
  • We report a case of CD56+ extranodal NK/T-cell lymphoma presenting as a duodenal ulcer bleeding.
  • [MeSH-major] Antigens, CD56 / metabolism. Duodenal Ulcer / diagnosis. Lymphoma, Extranodal NK-T-Cell / diagnosis. Peptic Ulcer Hemorrhage / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19844154.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Antigens, CD56
  •  go-up   go-down


62. Gregory TK, Wald D, Chen Y, Vermaat JM, Xiong Y, Tse W: Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics. J Hematol Oncol; 2009;2:23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Further prospective studies are needed to confirm if poorer risk NC-AML patients have improved clinical outcomes after more aggressive therapy.


63. Leoncini L, Delsol G, Gascoyne RD, Harris NL, Pileri SA, Piris MA, Stein H: Aggressive B-cell lymphomas: a review based on the workshop of the XI Meeting of the European Association for Haematopathology. Histopathology; 2005 Mar;46(3):241-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive B-cell lymphomas: a review based on the workshop of the XI Meeting of the European Association for Haematopathology.
  • The generic term aggressive B-cell lymphoma includes a variety of entities, each with particular diagnostic and therapeutic issues.
  • [MeSH-major] Lymphoma, B-Cell / classification. Lymphoma, B-Cell / pathology

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15720410.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 75
  •  go-up   go-down


64. Lu X, Chen J, Malumbres R, Cubedo Gil E, Helfman DM, Lossos IS: HGAL, a lymphoma prognostic biomarker, interacts with the cytoskeleton and mediates the effects of IL-6 on cell migration. Blood; 2007 Dec 15;110(13):4268-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HGAL, a lymphoma prognostic biomarker, interacts with the cytoskeleton and mediates the effects of IL-6 on cell migration.
  • HGAL is a newly identified germinal center (GC)-specific gene whose expression by the tumor cells correlates with a favorable prognosis in patients with diffuse large B-cell and classical Hodgkin lymphomas.
  • Inhibition of lymphocyte migration might contribute to the less aggressive clinical behavior of HGAL-expressing lymphomas.
  • [MeSH-major] Cell Movement. Cytoskeleton / pathology. Interleukin-6 / physiology. Lymphoma / pathology. Neoplasm Proteins / physiology

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Am J Nephrol. 1989;9(2):129-32 [2662771.001]
  • [Cites] Br J Haematol. 2001 Dec;115(3):554-62 [11736935.001]
  • [Cites] Nature. 1994 Mar 24;368(6469):339-42 [8127368.001]
  • [Cites] Br J Haematol. 1996 Jun;93(3):534-41 [8652370.001]
  • [Cites] J Immunol. 1996 Jun 1;156(11):4107-13 [8666776.001]
  • [Cites] Exp Hematol. 1997 Dec;25(13):1367-77 [9406996.001]
  • [Cites] J Exp Med. 1998 Nov 16;188(10):1895-906 [9815267.001]
  • [Cites] J Biomed Sci. 2004 Nov-Dec;11(6):940-9 [15591791.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2924-32 [15591113.001]
  • [Cites] Blood. 2005 May 15;105(10):3979-86 [15677569.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4849-56 [16493007.001]
  • [Cites] Blood. 2007 Jan 1;109(1):298-305 [16954503.001]
  • [Cites] Nature. 2007 Mar 1;446(7131):83-7 [17268470.001]
  • [Cites] Br J Haematol. 2007 Jun;137(6):578-90 [17489982.001]
  • [Cites] J Cell Biol. 2002 Dec 23;159(6):1087-96 [12486114.001]
  • [Cites] Blood. 2003 Jan 15;101(2):433-40 [12509382.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2639-44 [12604779.001]
  • [Cites] Am J Pathol. 2003 Jul;163(1):135-44 [12819018.001]
  • [Cites] Exp Cell Res. 2003 Sep 10;289(1):67-76 [12941605.001]
  • [Cites] Science. 2003 Dec 5;302(5651):1704-9 [14657486.001]
  • [Cites] N Engl J Med. 2004 Apr 29;350(18):1828-37 [15115829.001]
  • [Cites] Mol Immunol. 2004 Jul;41(6-7):631-43 [15220000.001]
  • [Cites] J Biol Chem. 2004 Aug 13;279(33):34227-39 [15175350.001]
  • [Cites] Eur J Immunol. 2004 Oct;34(10):2895-906 [15368306.001]
  • [Cites] Oncogene. 2004 Oct 18;23(48):8001-6 [15489917.001]
  • [Cites] FEBS Lett. 1987 Mar 23;213(2):316-8 [3556584.001]
  • [Cites] J Cell Sci. 2000 Oct;113 ( Pt 20):3551-62 [11017871.001]
  • (PMID = 17823310.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109335
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GCET2 protein, human; 0 / Interleukin-6; 0 / Neoplasm Proteins; EC 3.6.1.- / Myosin Type II
  • [Other-IDs] NLM/ PMC2234785
  •  go-up   go-down


65. Gorman EB, Chen L, Albanese J, Ratech H: Patterns of spectrin expression in B-cell lymphomas: loss of spectrin isoforms is associated with nodule-forming and germinal center-related lymphomas. Mod Pathol; 2007 Dec;20(12):1245-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although traditionally divided into erythroid and non-erythroid forms, the discovery of new spectrin isoforms in various tissues indicates that their distribution is not yet fully characterized.
  • Using tumor microarrays of paraffin blocks, we immunohistochemically studied 10 lymph nodes with reactive lymphoid hyperplasia and 94 lymph nodes involved by B-cell malignant lymphoma.
  • (1) loss of alphaII and betaII in follicular lymphoma, grades 2/3 and 3/3; nodular lymphocyte predominance Hodgkin's lymphoma; nodular sclerosis Hodgkin's lymphoma;.
  • (2) loss of betaI only in Burkitt lymphoma; and (3) loss of alphaII and betaI in mixed cellularity Hodgkin's lymphoma.
  • In contrast, follicular lymphoma, grade 1/3 and diffuse large B-cell lymphoma retained spectrin in 67-100% of cases.
  • The other lymphoma subtypes retained spectrin in greater than 50% of cases.
  • We identified the loss of particular spectrin isoforms in B-cell malignant lymphomas that have a nodular growth pattern and/or are believed to arise from germinal center B-cells, that is follicular lymphoma, grades 2/3 and 3/3; Burkitt lymphoma; nodular sclerosis Hodgkin's lymphoma; mixed cellularity Hodgkin's lymphoma; and nodular lymphocyte predominance Hodgkin's lymphoma.
  • The absence of particular spectrin isoforms may correlate with transformation or aggressive biologic behavior for some lymphoma subtypes.
  • [MeSH-major] Germinal Center / pathology. Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / pathology. Spectrin / biosynthesis

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17885671.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Protein Isoforms; 12634-43-4 / Spectrin
  •  go-up   go-down


66. Ninan MJ, Morrison VA: Therapeutic approaches to non-Hodgkin's lymphoma in the elderly patient. Expert Rev Hematol; 2009 Apr;2(2):173-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic approaches to non-Hodgkin's lymphoma in the elderly patient.
  • The incidence of non-Hodgkin's lymphoma (NHL) is increasing among all age groups, with a median age at diagnosis of 67 years.
  • With the increase in the geriatric population, there is a need for the development and validation of treatment strategies for NHL for these patients.
  • The disease incidence, characteristics and treatment approaches for both follicular and diffuse aggressive NHL histologies in elderly patients are reviewed, as well as the impact of aging on the care of these patients.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21083450.001).
  • [ISSN] 1747-4094
  • [Journal-full-title] Expert review of hematology
  • [ISO-abbreviation] Expert Rev Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


67. Moser EC, Noordijk EM, van Leeuwen FE, Baars JW, Thomas J, Carde P, Meerwaldt JH, van Glabbeke M, Kluin-Nelemans HC: Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study. Haematologica; 2006 Nov;91(11):1481-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study.
  • BACKGROUND AND OBJECTIVES: Second cancer has been associated with non-Hodgkin's Lymphoma (NHL) treatment, but few studies have addressed this issue considering specific treatments.
  • DESIGN AND METHODS: We estimated risk by standardized incidence ratios (SIR) and absolute excess risk (AER) based on general population rates (European Network of Cancer Registries) in 748 patients (aged 15-82 years) treated for aggressive NHL in four successive EORTC (European Organization for Research on Treatment of Cancer) trials.
  • The cause of death was NHL in 79% of the patients; 4% died of second cancer (median survival 8.9 (0.8- 20.5) years).
  • Cancer risk appeared age-related: in young patients high risks were observed for leukemia (SIR 16.7,95% CI 1.4-93.1,AER 5.0), Hodgkin's lymphoma (SIR 60.1,95% CI 12.4-175.2, AER 15.7), colorectal cancer (SIR 12.5, 95% CI 2.6-36.5, AER 14.7) and lung cancer (SIR 15.4; 95% CI 4.2-39.4, AER 19.8), while risk in patients older than 45 years matched than that in the normal population.
  • INTERPRETATION AND CONCLUSIONS: Half of the patients die of aggressive NHL before living long enough to experience second cancer.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / epidemiology. Neoplasms, Second Primary / epidemiology

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17043014.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


68. Vahid B, Machare-Delgado E, Marik PE: Pulmonary manifestations of peripheral T-cell lymphoma: case report and review of the literature. Clin Respir J; 2007 Dec;1(2):114-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary manifestations of peripheral T-cell lymphoma: case report and review of the literature.
  • INTRODUCTION: Peripheral T-cell lymphomas (PTCL) represent approximately 10% of non-Hodgkin's lymphomas.
  • T-cell receptor gamma gene rearrangement by polymerase chain reaction confirmed the diagnosis of peripheral T-cell lymphoma.
  • Unfortunately, the patient died because of refractory and aggressive disease.
  • The subject of pulmonary involvement in peripheral T-cell lymphoma is discussed.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / complications. Multiple Pulmonary Nodules / etiology

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20298290.001).
  • [ISSN] 1752-699X
  • [Journal-full-title] The clinical respiratory journal
  • [ISO-abbreviation] Clin Respir J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 10
  •  go-up   go-down


69. Kachlany SC: Aggregatibacter actinomycetemcomitans leukotoxin: from threat to therapy. J Dent Res; 2010 Jun;89(6):561-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aggregatibacter actinomycetemcomitans is a Gram-negative bacterium that colonizes the human oral cavity and is the causative agent for localized aggressive periodontitis (LAP), an aggressive form of periodontal disease that occurs in adolescents. A. actinomycetemcomitans secretes a protein toxin, leukotoxin (LtxA), which helps the bacterium evade the host immune response during infection.
  • [MeSH-minor] Actinobacillus Infections / immunology. Actinobacillus Infections / microbiology. Adolescent. Aggressive Periodontitis / immunology. Aggressive Periodontitis / microbiology. Humans. Immunosuppressive Agents / therapeutic use. Leukocytes / drug effects

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7295-300 [12756291.001]
  • [Cites] Infect Immun. 2003 Aug;71(8):4448-55 [12874324.001]
  • [Cites] Int Dent J. 2003;53 Suppl 3:200-7 [12875309.001]
  • [Cites] Infect Immun. 2000 Nov;68(11):6094-100 [11035711.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):376-88 [11208829.001]
  • [Cites] Microb Pathog. 2001 Jun;30(6):359-68 [11399142.001]
  • [Cites] J Biol Chem. 2001 Aug 10;276(32):30326-34 [11369755.001]
  • [Cites] J Dent Res. 2001 Jun;80(6):1580-3 [11499517.001]
  • [Cites] Microbiology. 2001 Oct;147(Pt 10):2749-56 [11577154.001]
  • [Cites] Infect Immun. 2001 Dec;69(12):7625-34 [11705942.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jun;87(12):4776-80 [2112747.001]
  • [Cites] Nucleic Acids Res. 1990 Sep 11;18(17):5291 [2402457.001]
  • [Cites] Nucleic Acids Res. 1990 Sep 11;18(17):5292 [2402458.001]
  • [Cites] Infect Immun. 1991 Apr;59(4):1394-401 [2004819.001]
  • [Cites] Infect Immun. 1991 Sep;59(9):2955-62 [1652556.001]
  • [Cites] Infect Immun. 1991 Sep;59(9):3267-72 [1879940.001]
  • [Cites] Infect Immun. 1991 Dec;59(12):4599-605 [1937819.001]
  • [Cites] Leukemia. 1991 Oct;5(10):848-53 [1683677.001]
  • [Cites] J Clin Microbiol. 1994 May;32(5):1288-94 [8051258.001]
  • [Cites] J Biol Chem. 1994 Dec 9;269(49):31289-95 [7983074.001]
  • [Cites] Science. 1994 Dec 23;266(5193):1992-6 [7801126.001]
  • [Cites] Microb Pathog. 1995 May;18(5):307-21 [7476096.001]
  • [Cites] Rev Inst Med Trop Sao Paulo. 1995 May-Jun;37(3):215-7 [8525266.001]
  • [Cites] Infect Immun. 1996 Jul;64(7):2724-9 [8698501.001]
  • [Cites] Microbiology. 1996 Apr;142 ( Pt 4):963-70 [8936323.001]
  • [Cites] Annu Rev Med. 1997;48:25-33 [9046942.001]
  • [Cites] J Biol Chem. 1997 Nov 28;272(48):30463-9 [9374538.001]
  • [Cites] Mol Gen Genet. 1997 Oct;256(3):306-19 [9393456.001]
  • [Cites] J Clin Microbiol. 1997 Dec;35(12):3037-42 [9399490.001]
  • [Cites] Microbiol Mol Biol Rev. 1998 Jun;62(2):309-33 [9618444.001]
  • [Cites] Infect Immun. 1998 Sep;66(9):4474-83 [9712803.001]
  • [Cites] J Immunol. 1999 Apr 15;162(8):4773-80 [10202019.001]
  • [Cites] Leuk Res. 1999 May;23(5):483-8 [10374862.001]
  • [Cites] Trends Microbiol. 1999 Sep;7(9):356-61 [10470043.001]
  • [Cites] Periodontol 2000. 1999 Jun;20:82-121 [10522224.001]
  • [Cites] Periodontol 2000. 1999 Jun;20:122-35 [10522225.001]
  • [Cites] EMBO J. 2004 Nov 24;23(23):4538-49 [15549136.001]
  • [Cites] J Immunol. 2005 Feb 15;174(4):2228-34 [15699156.001]
  • [Cites] Int J Artif Organs. 2009 Sep;32(9):545-54 [19851978.001]
  • [Cites] Leuk Res. 2010 Jun;34(6):777-85 [19747730.001]
  • [Cites] Infect Immun. 1990 Apr;58(4):920-9 [2318535.001]
  • [Cites] J Periodontol. 1999 Nov;70(11):1261-8 [10588488.001]
  • [Cites] J Clin Microbiol. 2000 Mar;38(3):1196-9 [10699021.001]
  • [Cites] Clin Oral Investig. 1999 Dec;3(4):161-7 [10803129.001]
  • [Cites] J Periodontol. 2000 Jun;71(6):912-22 [10914794.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2003 Aug 1;23(8):1405-11 [12816879.001]
  • [Cites] Antimicrob Agents Chemother. 2003 Sep;47(9):3030-3 [12937021.001]
  • [Cites] Infect Immun. 2003 Oct;71(10):5640-9 [14500484.001]
  • [Cites] Res Microbiol. 2003 Nov;154(9):645-53 [14596902.001]
  • [Cites] Immunol Lett. 2004 Mar 29;92(1-2):51-4 [15081527.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 Jul;75(7):951-7 [15201348.001]
  • [Cites] J Periodontol. 1976 Jul;47(7):373-9 [781209.001]
  • [Cites] Infect Immun. 1979 Apr;24(1):233-43 [222679.001]
  • [Cites] Infect Immun. 1979 Jul;25(1):427-39 [113347.001]
  • [Cites] Infect Immun. 1980 Apr;28(1):258-68 [6155347.001]
  • [Cites] Arch Oral Biol. 1981;26(8):671-6 [6172101.001]
  • [Cites] Infect Immun. 1984 Feb;43(2):700-5 [6319288.001]
  • [Cites] J Clin Periodontol. 1985 Jan;12(1):1-20 [3882766.001]
  • [Cites] Infect Immun. 1988 May;56(5):1162-6 [3258584.001]
  • [Cites] Blood. 1988 Oct;72(4):1431-4 [3048446.001]
  • [Cites] Biochem Biophys Res Commun. 1989 Feb 28;159(1):256-62 [2647082.001]
  • [Cites] Oral Microbiol Immunol. 1987 Sep;2(3):97-104 [3507626.001]
  • [Cites] Infect Immun. 1989 May;57(5):1465-9 [2707855.001]
  • [Cites] J Biol Chem. 1989 Sep 15;264(26):15451-6 [2670940.001]
  • [Cites] Microb Pathog. 1991 Aug;11(2):111-21 [1961107.001]
  • [Cites] J Periodontol. 1991 Oct;62(10):608-16 [1770420.001]
  • [Cites] Oral Microbiol Immunol. 1992 Feb;7(1):24-7 [1528620.001]
  • [Cites] Arch Oral Biol. 1992 Oct;37(10):813-9 [1359858.001]
  • [Cites] J Dent Res. 1993 Oct;72(10):1366-73 [8408878.001]
  • [Cites] EMBO J. 1993 Sep;12(9):3357-64 [8253063.001]
  • [Cites] Infect Immun. 1994 Feb;62(2):501-8 [8300209.001]
  • [Cites] Infect Immun. 2005 Jun;73(6):3758-63 [15908408.001]
  • [Cites] Circulation. 2005 Jul 5;112(1):19-24 [15983248.001]
  • [Cites] Nat Rev Immunol. 2005 Jul;5(7):546-59 [15965491.001]
  • [Cites] Mol Membr Biol. 2005 Jan-Apr;22(1-2):29-39 [16092522.001]
  • [Cites] Biochemistry. 2005 Aug 23;44(33):11115-21 [16101295.001]
  • [Cites] Mol Microbiol. 2006 Jan;59(1):99-112 [16359321.001]
  • [Cites] Mol Microbiol. 2006 Jan;59(1):126-41 [16359323.001]
  • [Cites] Cell Microbiol. 2006 Jan;8(1):72-84 [16367867.001]
  • [Cites] Microb Pathog. 2006 Feb;40(2):48-55 [16414241.001]
  • [Cites] Infect Immun. 2006 Apr;74(4):2015-21 [16552030.001]
  • [Cites] Periodontol 2000. 2006;42:114-57 [16930309.001]
  • [Cites] Cell Microbiol. 2006 Nov;8(11):1753-67 [16827908.001]
  • [Cites] J Bacteriol. 2006 Dec;188(24):8658-61 [17041062.001]
  • [Cites] Gene. 2007 Feb 15;388(1-2):83-92 [17116373.001]
  • [Cites] J Biol Chem. 2007 Apr 20;282(16):11827-35 [17324923.001]
  • [Cites] J Dent Res. 2007 Jul;86(7):618-22 [17586707.001]
  • [Cites] Infect Immun. 2007 Sep;75(9):4490-7 [17635874.001]
  • [Cites] Infect Immun. 2007 Oct;75(10):4851-6 [17635865.001]
  • [Cites] Cell Microbiol. 2007 Nov;9(11):2689-99 [17587330.001]
  • [Cites] J Clin Microbiol. 2007 Dec;45(12):3859-69 [17942658.001]
  • [Cites] J Clin Periodontol. 2008 Feb;35(2):89-105 [18199146.001]
  • [Cites] Lancet. 2008 Jan 19;371(9608):237-42 [18207019.001]
  • [Cites] Microbiology. 2008 Feb;154(Pt 2):528-38 [18227257.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Apr 8;105(14):5355-60 [18375764.001]
  • [Cites] Infect Immun. 2008 Aug;76(8):3561-8 [18541661.001]
  • [Cites] J Bacteriol. 2008 Sep;190(17):5972-80 [18621903.001]
  • [Cites] Infect Immun. 2009 Feb;77(2):694-8 [19015247.001]
  • [Cites] J Clin Periodontol. 2009 May;36(5):406-10 [19419440.001]
  • [Cites] Gene. 2009 Aug 15;443(1-2):42-7 [19450669.001]
  • [Cites] Microb Pathog. 2000 Nov;29(5):267-78 [11031121.001]
  • [Cites] Cell Microbiol. 2001 Dec;3(12):811-23 [11736993.001]
  • [Cites] Microb Pathog. 2002 Jan;32(1):1-13 [11782116.001]
  • [Cites] J Clin Microbiol. 2002 Apr;40(4):1181-7 [11923328.001]
  • [Cites] Clin Lymphoma. 2002 Mar;2(4):222-8 [11970761.001]
  • [Cites] FEMS Immunol Med Microbiol. 2002 Sep 6;34(1):45-50 [12208605.001]
  • [Cites] Arch Oral Biol. 2002 Aug;47(8):613-8 [12221019.001]
  • [Cites] Microbiology. 2002 Dec;148(Pt 12):3993-4001 [12480903.001]
  • [Cites] Eur J Oral Sci. 2003 Jun;111(3):209-15 [12786951.001]
  • (PMID = 20200418.001).
  • [ISSN] 1544-0591
  • [Journal-full-title] Journal of dental research
  • [ISO-abbreviation] J. Dent. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Toxins; 0 / Cytotoxins; 0 / Exotoxins; 0 / Immunosuppressive Agents; 0 / leukotoxin
  • [Number-of-references] 113
  • [Other-IDs] NLM/ PMC3144085
  •  go-up   go-down


70. Kumar J, Seith A, Bakhshi S, Sharma R, Kumar A: Multifocal non-Hodgkin lymphoma in an infant with cardiac involvement: whole-body MR imaging. Pediatr Radiol; 2007 Mar;37(3):321-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifocal non-Hodgkin lymphoma in an infant with cardiac involvement: whole-body MR imaging.
  • Non-Hodgkin lymphoma (NHL) is rare in infancy, and we present a case of aggressive NHL of T-cell lineage in an infant with multifocal bone, cardiac, mediastinal nodal, paranasal sinus, calvarial, and soft-tissue deposits on presentation that were detected on whole-body MRI.
  • [MeSH-major] Heart Neoplasms / diagnosis. Lymphoma, T-Cell / diagnosis. Magnetic Resonance Imaging / methods. Whole Body Imaging

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Radiol. 2004 Jun;14 (6):1074-81 [14986048.001]
  • [Cites] Pediatr Radiol. 2005 Aug;35(8):766-73 [15864576.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):359-72 [7844597.001]
  • [Cites] Radiographics. 2004 Sep-Oct;24(5):1317-30 [15371611.001]
  • [Cites] AJR Am J Roentgenol. 2001 Jul;177(1):229-36 [11418435.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Dec;26(12):852-4 [15591913.001]
  • [Cites] Eur Radiol. 2004 Oct;14 (10 ):1829-41 [15365752.001]
  • [Cites] AJR Am J Roentgenol. 1997 Dec;169(6):1655-61 [9393186.001]
  • (PMID = 17262185.001).
  • [ISSN] 0301-0449
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


71. Alshenawy HA: Prognostic significance of vascular endothelial growth factor, basic fibroblastic growth factor, and microvessel density and their relation to cell proliferation in B-cell non-Hodgkin's lymphoma. Ann Diagn Pathol; 2010 Oct;14(5):321-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of vascular endothelial growth factor, basic fibroblastic growth factor, and microvessel density and their relation to cell proliferation in B-cell non-Hodgkin's lymphoma.
  • However, their role in angiogenesis and proliferation in B-cell non-Hodgkin's lymphoma (B-NHL) is unclear.
  • Seventy cases of B-NHL besides 5 cases with reactive lymphadenitis were collected randomly and classified according to World Health Organization classification, Ann Arbor staging.
  • In conclusion, as the tumor becomes more aggressive, it also becomes independent of stromal paracrine factors by the establishment of an autocrine VEGF and b-FGF stimulation that can increase its angiogenesis and proliferation.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Fibroblast Growth Factor 2 / metabolism. Lymphoma, B-Cell / pathology. Neovascularization, Pathologic / pathology. Vascular Endothelial Growth Factor A / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20850693.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2
  •  go-up   go-down


72. Kaufman DA, Hershfield MS, Bocchini JA, Moissidis IJ, Jeroudi M, Bahna SL: Cerebral lymphoma in an adenosine deaminase-deficient patient with severe combined immunodeficiency receiving polyethylene glycol-conjugated adenosine deaminase. Pediatrics; 2005 Dec;116(6):e876-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebral lymphoma in an adenosine deaminase-deficient patient with severe combined immunodeficiency receiving polyethylene glycol-conjugated adenosine deaminase.
  • At 10 years of age, after presenting with headaches and cranial nerve deficits, he was diagnosed with Epstein-Barr virus-positive malignant brain lymphoma.
  • It did not respond to various regimens of aggressive chemotherapy, and the patient expired 5 months later.
  • [MeSH-major] Adenosine Deaminase / therapeutic use. Brain Neoplasms / complications. Epstein-Barr Virus Infections / complications. Lymphoma / complications. Severe Combined Immunodeficiency / complications. Severe Combined Immunodeficiency / drug therapy


73. Paydas S, Ergin M, Erdogan S, Seydaoglu G: Prognostic significance of EBV-LMP1 and VEGF-A expressions in non-Hodgkin's lymphomas. Leuk Res; 2008 Sep;32(9):1424-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of EBV-LMP1 and VEGF-A expressions in non-Hodgkin's lymphomas.
  • BACKGROUND AND AIM: EBV is an important virus in the pathogenesis of NHL.
  • The viral latent protein LMP1, may play a role by inducing expression of angiogenic factors In this study EBV-LMP1 and VEGF-A expressions have been studied in cases with NHL and prognostic significance of these has been evaluated.
  • PATIENTS AND METHODS: One hundred seventy-seven cases (60 had low grade lymphoma (LGL), 117 had aggressive lymphoma (AL)) with NHL have been included in this analysis.
  • There was an association between VEGF-A and aggressive histology (OR: 2.0, 95% CI: 1.1-3.8, p=0.031).
  • EBV positivity was associated with VEGF-A expression in diffuse large B cell lymphoma (DLBCL) (0.045).
  • Targeting both the angiogenesis and EBV may be important in the therapy of cases with NHL expressing EBV and/or VEGF-A.
  • [MeSH-major] Lymphoma, B-Cell / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Non-Hodgkin / metabolism. Vascular Endothelial Growth Factor A / metabolism. Viral Matrix Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18282597.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / Viral Matrix Proteins
  •  go-up   go-down


74. Skugor ND, Perić Z, Vrhovac R, Radić-Kristo D, Kardum-Skelin I, Jaksić B: Diffuse large B-cell lymphoma in patient after treatment of angioimmunoblastic T-cell lymphoma. Coll Antropol; 2010 Mar;34(1):241-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma in patient after treatment of angioimmunoblastic T-cell lymphoma.
  • Relatively few cases of Epstein-Barr (EBV)-positive B-cell lymphomas arising in patients with angioimmunoblastic T-cell lymphoma (AITL) have been reported.
  • We report a case of AITL in which diffuse large B-cell lymphoma arose 13 months after the initial diagnosis of AITL.
  • Various authors postulated that immunodeficiency in AITL patients together with immunosuppressive effects of cytotoxic drugs, may be responsible for EBV-induced proliferation of latently or newly EBV-infected B-cells with eventual clonal selection and progression to aggressive B-cell lymphoma.
  • [MeSH-major] Immunoblastic Lymphadenopathy / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, T-Cell, Peripheral / pathology. Neoplasms, Second Primary / pathology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20432757.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


75. Reyes F, Lepage E, Ganem G, Molina TJ, Brice P, Coiffier B, Morel P, Ferme C, Bosly A, Lederlin P, Laurent G, Tilly H, Groupe d'Etude des Lymphomes de l'Adulte (GELA): ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med; 2005 Mar 24;352(12):1197-205
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma.
  • BACKGROUND: Chemoradiotherapy is standard treatment for localized aggressive lymphoma.
  • To determine the optimal therapy for nonelderly persons with low-risk localized lymphoma, we conducted a randomized trial comparing chemoradiotherapy with chemotherapy alone.
  • METHODS: Previously untreated patients less than 61 years old with localized stage I or II aggressive lymphoma and no adverse prognostic factors according to the International Prognostic Index were randomly assigned to three cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus involved-field radiotherapy (329 patients) or chemotherapy alone with dose-intensified doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (ACVBP) plus sequential consolidation (318 patients).
  • CONCLUSIONS: In patients under 61 years of age, chemotherapy with three cycles of ACVBP followed by sequential consolidation is superior to three cycles of CHOP plus radiotherapy for the treatment of low-risk localized lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINDESINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Massachusetts Medical Society.
  • [CommentIn] N Engl J Med. 2005 Jun 9;352(23):2449-51; author reply 2449-51 [15944432.001]
  • [CommentIn] N Engl J Med. 2005 Mar 24;352(12):1250-2 [15788502.001]
  • [CommentIn] N Engl J Med. 2005 Jun 9;352(23):2449-51; author reply 2449-51 [15948267.001]
  • [CommentIn] N Engl J Med. 2005 Jun 9;352(23):2449-51; author reply 2449-51 [15948268.001]
  • (PMID = 15788496.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; RSA8KO39WH / Vindesine; VB0R961HZT / Prednisone; CHOP protocol; LNH 87 protocol
  •  go-up   go-down


76. Damaj G, Bouabdallah R, Vey N, Bilger K, Mohty M, Gastaut JA: Single-agent thalidomide induces response in T-cell lymphoma. Eur J Haematol; 2005 Feb;74(2):169-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-agent thalidomide induces response in T-cell lymphoma.
  • T-cell lymphoma is an aggressive lymphoma that cannot be cured despite aggressive therapy, including autologous stem cell transplantation.
  • We report three cases of relapsed refractory T-cell lymphoma treated with thalidomide with a good tumor response.
  • [MeSH-major] Immunosuppressive Agents / administration & dosage. Lymphoma, T-Cell / drug therapy. Neoplasm Recurrence, Local / drug therapy. Thalidomide / administration & dosage

  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) Blackwell Munksgaard 2005
  • (PMID = 15654910.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


77. Ben Salah H, Ghorbel L, Krichen MS, Bellaaj H, Elloumi M, Frikha M, Daoud J: [The value of radiotherapy in the treatment of aggressive and localised gastric lymphomas]. Cancer Radiother; 2009 Jan;13(1):11-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The value of radiotherapy in the treatment of aggressive and localised gastric lymphomas].
  • PURPOSE: To evaluate the treatment results of localised aggressive gastric lymphomas with favourable prognosis using chemotherapy and radiotherapy.
  • PATIENTS AND METHODS: Between February 1993 and December 2004, nine patients with primary gastric high-grade lymphoma have been treated by the Lymphoma Committee of Sfax (Tunisia).
  • Histological type was the large cell B lymphoma in 100% of the cases.
  • CONCLUSION: Chemotherapy associated with radiotherapy can be proposed to patients having localised and aggressive primary gastric lymphoma with favourable prognosis, since this treatment is well tolerated and provides satisfactory control of the disease.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / radiotherapy. Stomach Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19091618.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CEOP protocol 1; CHOP protocol
  •  go-up   go-down


78. Giuliante F, Sarno G, Ardito F, Pierconti F: Primary hepatic leiomyosarcoma in a young man after Hodgkin's disease: diagnostic pitfalls and therapeutic challenge. Tumori; 2009 May-Jun;95(3):374-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary hepatic leiomyosarcoma in a young man after Hodgkin's disease: diagnostic pitfalls and therapeutic challenge.
  • PATIENT CASE: A 26-year-old male patient with a previous history of radiochemotherapy treatment for Hodgkin's lymphoma was referred to our unit with a histological and radiological diagnosis of primary hepatic leiomyosarcoma.
  • CONCLUSIONS: The challenges and peculiarities of this case are related to the rarity of the tumor, its accidental discovery without immediate suspicion of its nature, its very aggressive behavior that was only partly controlled by chemotherapy, and the unusual expression of a neuroendocrine phenotypic feature with high serum chromogranin A levels.
  • [MeSH-major] Hodgkin Disease. Leiomyosarcoma. Liver Neoplasms. Neoplasms, Second Primary


79. Chang DT, Mendenhall NP, Lynch JW, Morris CG, Olivier KR: Long-term outcomes for stage I-II aggressive non-Hodgkin lymphoma of Waldeyer's ring. Am J Clin Oncol; 2009 Jun;32(3):233-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes for stage I-II aggressive non-Hodgkin lymphoma of Waldeyer's ring.
  • PURPOSE: To determine the long-term outcome of patients treated at the University of Florida for aggressive non-Hodgkin lymphoma (NHL) of Waldeyer's ring.
  • MATERIALS AND METHODS: Forty-six patients treated with radiotherapy (RT) at the University of Florida from 1964 to 2006 for biopsy-proven aggressive NHL of Waldeyer's ring were included in this study.
  • CONCLUSIONS: Similar to other sites, out-of-field recurrences are the primary pattern of failure for NHL of Waldeyer's ring.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy. Tonsillar Neoplasms / drug therapy. Tonsillar Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433961.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Ejaz A, Wenig BM: Sinonasal undifferentiated carcinoma: clinical and pathologic features and a discussion on classification, cellular differentiation, and differential diagnosis. Adv Anat Pathol; 2005 May;12(3):134-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sinonasal undifferentiated carcinoma (SNUC) is an uncommon, highly aggressive, and clinicopathologically distinctive carcinoma of uncertain histogenesis.
  • The treatment of SNUC includes aggressive multimodality therapy, including surgical resection and adjuvant therapy (ie, radiotherapy, chemotherapy).
  • [MeSH-minor] Adult. Aged. Carcinoma, Neuroendocrine / pathology. Diagnosis, Differential. Esthesioneuroblastoma, Olfactory / pathology. Humans. Lymphoma, T-Cell, Cutaneous / pathology. Male. Melanoma / pathology. Middle Aged. Nasal Cavity / pathology. Nose Neoplasms / pathology. Prognosis. Rhabdomyosarcoma / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Sinonasal undifferentiated carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15900114.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 29
  •  go-up   go-down


81. Navarro JT, Lloveras N, Ribera JM, Oriol A, Mate JL, Feliu E: The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy. Haematologica; 2005 May;90(5):704-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy.
  • In the era of highly active antiretroviral treatment (HAART), the prognosis of AIDS-related lymphomas might be similar to that of aggressive B-cell lymphomas in human immunodeficiency (HIV)-negative patients.
  • In this study we found that HIV-infected patients with diffuse large B-cell lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone (CHOP) and HAART showed a similar response rate to chemotherapy, disease-free survival and overall survival as those of HIV-negative patients receiving CHOP.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. HIV Infections / mortality. Lymphoma, AIDS-Related / mortality. Lymphoma, Large B-Cell, Diffuse / mortality


82. Martín-Subero JI, Kreuz M, Bibikova M, Bentink S, Ammerpohl O, Wickham-Garcia E, Rosolowski M, Richter J, Lopez-Serra L, Ballestar E, Berger H, Agirre X, Bernd HW, Calvanese V, Cogliatti SB, Drexler HG, Fan JB, Fraga MF, Hansmann ML, Hummel M, Klapper W, Korn B, Küppers R, Macleod RA, Möller P, Ott G, Pott C, Prosper F, Rosenwald A, Schwaenen C, Schübeler D, Seifert M, Stürzenhofecker B, Weber M, Wessendorf S, Loeffler M, Trümper L, Stein H, Spang R, Esteller M, Barker D, Hasenclever D, Siebert R, Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe: New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood; 2009 Mar 12;113(11):2488-97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling.
  • Here, we have performed a microarray-based DNA methylation profiling of 83 mature aggressive B-cell non-Hodgkin lymphomas (maB-NHLs) characterized for their morphologic, genetic, and transcriptional features, including molecular Burkitt lymphomas and diffuse large B-cell lymphomas.
  • By supervised analyses, we identified 56 genes de novo methylated in all lymphoma subtypes studied and 22 methylated in a lymphoma subtype-specific manner.
  • Remarkably, the group of genes de novo methylated in all lymphoma subtypes was significantly enriched for polycomb targets in embryonic stem cells.
  • [MeSH-major] Cell Transformation, Neoplastic / genetics. Epigenesis, Genetic / physiology. Gene Expression Profiling. Genomics / methods. Lymphoma, B-Cell / genetics. Oligonucleotide Array Sequence Analysis

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19075189.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Investigator] Barth TF; Bernd HW; Cogliatti SB; Feller AC; Hansmann ML; Hummel M; Klapper W; Möller P; Müller-Hermelink HK; Ott G; Rosenwald A; Stein H; Szcepanowski M; Wacker HH; Behrmann P; Daniel P; Dierlammm J; Haralambieva E; Harder L; Holterhus PM; Küppers R; Kube D; Lichter P; Martín-Subero JI; Murga-Peñas EM; Pott C; Pscherer A; Schwaenen C; Siebert R; Trautmann H; Vockerodt M; Wessendorf S; Bentink S; Berger H; Hasenclever D; Kreuz M; Loeffler M; Rosolowski M; Spang R; Stürzenhofecker B; Trümper L; Wehner M
  •  go-up   go-down


83. Nemets A, Ronen M, Lugassy G: Chronic paraneoplastic cutaneous syndrome preceding an indolent variant of mantle cell lymphoma: favorable response to rituximab. Acta Haematol; 2006;115(1-2):113-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic paraneoplastic cutaneous syndrome preceding an indolent variant of mantle cell lymphoma: favorable response to rituximab.
  • Mantle cell lymphoma (MCL) is an aggressive type of malignant lymphoma with short median survival despite conventional therapy.
  • Repeated skin biopsies did not show involvement by the lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Lymphoma, Mantle-Cell / drug therapy. Neoplasms, Second Primary / drug therapy. Paraneoplastic Syndromes / drug therapy. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • [CommentIn] Acta Haematol. 2006;116(3):228 [17016048.001]
  • (PMID = 16424661.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


84. Apostolopoulos DJ, Papandrianos NI, Symeonidis A, Spyridonidis T, Alexiou S, Zampakis P, Savvopoulos C, Vassilakos PJ, Matsouka P: Technetium-99m depreotide imaging by single photon emission tomography/low resolution computed tomography in malignant lymphomas: comparison with gallium-67 citrate. Ann Nucl Med; 2010 Nov;24(9):639-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Previous studies have demonstrated the feasibility of targeting lymphoma lesions with somatostatin receptor binding agents, mainly with In-111-pentetreotide.
  • METHODS: One-hundred and six patients, 47 with Hodgkin's (HL) and 59 with various types of non-Hodgkin's lymphoma (NHL), were imaged with both Tc-99m depreotide and Ga-67 citrate.
  • RESULTS: In most HL, intermediate- and low-grade B-cell, as well as in T-cell NHL, depreotide depicted more lesions than Ga-67 and/or exhibited higher tumor uptake.
  • The opposite was true in aggressive B-cell NHL.
  • However, there were notable exceptions in all lymphoma subtypes.
  • However, advanced HL and NHL cases were frequently downstaged, due to low sensitivity for abdominal lymph node (22.7%), liver (45.5%) and bone marrow involvement (36.4%).
  • Post-therapy, however, depreotide scintigraphy seems useful in the evaluation of certain anatomic areas, particularly in non-aggressive lymphoma types.
  • If fluorodeoxyglucose positron emission tomography is not available or in case of certain indolent lymphoma types, Tc-99m depreotide may have a role as an adjunct to conventional imaging procedures.
  • [MeSH-major] Citrates. Gallium. Lymphoma / diagnosis. Organotechnetium Compounds. Somatostatin / analogs & derivatives. Tomography, Emission-Computed, Single-Photon / methods. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. GALLIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20799079.001).
  • [ISSN] 1864-6433
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Citrates; 0 / Organotechnetium Compounds; 27905-02-8 / gallium citrate; 51110-01-1 / Somatostatin; 9M48M2SF02 / technetium Tc 99m depreotide; CH46OC8YV4 / Gallium
  •  go-up   go-down


85. Stam RW, den Boer ML, Passier MM, Janka-Schaub GE, Sallan SE, Armstrong SA, Pieters R: Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia. Leukemia; 2006 Feb;20(2):264-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MLL rearranged acute lymphoblastic leukemia (MLL) is an aggressive type of acute lymphoblastic leukemia (ALL), diagnosed predominantly in infants (<1 years of age).
  • In contrast, FHIT methylation in infant and non-infant ALL patients carrying germ line MLL was found in only approximately 60% (P< or =0.004).
  • [MeSH-major] Acid Anhydride Hydrolases / genetics. Gene Silencing. Myeloid-Lymphoid Leukemia Protein / genetics. Neoplasm Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16357833.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MLL protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / fragile histidine triad protein; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


86. Dunphy CH, DeMello DE, Gale GB: Pediatric CD56+ anaplastic large cell lymphoma: a review of the literature. Arch Pathol Lab Med; 2006 Dec;130(12):1859-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric CD56+ anaplastic large cell lymphoma: a review of the literature.
  • We encountered a pediatric case of CD56+, anaplastic lymphoma kinase-positive ALCL of apparent natural killer-like T-cell origin (showing positivity for CD2, cytoplasmic CD3, surface CD3 partial positivity, CD7, CD8, CD56, TIA-1, and granzyme B).
  • The patient had initial lymph node and multiple sites of cutaneous involvement and an aggressive clinical course with multiple recurrences after varying periods of complete remission.
  • CONCLUSIONS: Our review did not confirm a uniformly aggressive clinical course in pediatric cases of CD56+ ALCLs.
  • [MeSH-major] Antigens, CD56 / metabolism. Lymphoma, Large-Cell, Anaplastic / metabolism

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17149964.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD56
  • [Number-of-references] 22
  •  go-up   go-down


87. Barr PM, Lazarus HM, Cooper BW, Schluchter MD, Panneerselvam A, Jacobberger JW, Hsu JW, Janakiraman N, Simic A, Dowlati A, Remick SC: Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant. Am J Hematol; 2009 Aug;84(8):484-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant.
  • Bryostatin 1, isolated from a marine bryozoan, enhances the efficacy of cytotoxic agents through modulation of the protein kinase C pathway and is active in combination with vincristine for diffuse large B-cell lymphoma.
  • We tested the efficacy and safety of bryostatin 1 50 microg/m(2) given over 24 hr and vincristine 1.4 mg/m(2) on days 1 and 15 every 28 days in aggressive B-cell non-Hodgkin lymphoma (NHL) relapsing after autologous stem cell transplantation.
  • Bryostatin 1 and vincristine have efficacy in select patients with aggressive NHL.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19536846.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / UL1 RR024989; United States / NCI NIH HHS / CA / U01 CA062502; United States / NCI NIH HHS / CA / CA62502; United States / NCRR NIH HHS / RR / M01-RR-00080; United States / NCI NIH HHS / CA / U01 CA062502-15; United States / NCRR NIH HHS / RR / M01 RR000080
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Antigens, CD5; 0 / Bryostatins; 37O2X55Y9E / bryostatin 1; 5J49Q6B70F / Vincristine; EC 2.7.11.13 / Protein Kinase C
  • [Other-IDs] NLM/ NIHMS134792; NLM/ PMC4465083
  •  go-up   go-down


88. Swinney RM, Wall DA, Thomas PJ, Grimley MS, Taylor C, Tomlinson GE: Familial childhood leukemia cluster with multiple aggressive early-onset hematological malignancies. Leuk Lymphoma; 2006 May;47(5):930-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Familial childhood leukemia cluster with multiple aggressive early-onset hematological malignancies.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16753883.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


89. Tucci A, Ferrari S, Bottelli C, Borlenghi E, Drera M, Rossi G: A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. Cancer; 2009 Oct 1;115(19):4547-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy.
  • BACKGROUND: The authors set out to analyze if a simple comprehensive geriatric assessment (CGA) could objectively identify elderly patients with diffuse large cell lymphoma (DLCL) who can be effectively treated with anthracycline-containing immunochemotherapy.
  • These subgroups did not differ in any geriatric or lymphoma-related characteristic.
  • Lymphoma rather than toxicity was the main cause of failure/death also among unfit patients treated aggressively.
  • Further study is needed to discern why unfit patients seem to have poor outcomes because of poor tolerance but also because of lymphoma refractoriness to intensive therapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Geriatric Assessment. Lymphoma, Large B-Cell, Diffuse / therapy

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 American Cancer Society.
  • (PMID = 19562776.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


90. Fischer S, Mann G, Konrad M, Metzler M, Ebetsberger G, Jones N, Nadel B, Bodamer O, Haas OA, Schmitt K, Panzer-Grümayer ER: Screening for leukemia- and clone-specific markers at birth in children with T-cell precursor ALL suggests a predominantly postnatal origin. Blood; 2007 Oct 15;110(8):3036-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Childhood T-cell precursor acute lymphoblastic leukemia (TCP ALL) is an aggressive disease with a presumably short latency that differs in many biologic respects from B-cell precursor (BCP) ALL.
  • [MeSH-major] Biomarkers, Tumor / genetics. Gene Rearrangement, T-Lymphocyte / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17557895.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / LIM Domain Proteins; 0 / LMO2 protein, human; 0 / Metalloproteins; 0 / Proto-Oncogene Proteins; 0 / Receptor, Notch1; 135471-20-4 / TAL1 protein, human
  •  go-up   go-down


91. Fellows GA, Wright AJ, Sibtain NA, Rich P, Opstad KS, McIntyre DJ, Bell BA, Griffiths JR, Howe FA: Combined use of neuroradiology and 1H-MR spectroscopy may provide an intervention limiting diagnosis of glioblastoma multiforme. J Magn Reson Imaging; 2010 Nov;32(5):1038-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • GBM is the most common and aggressive primary brain tumor, with mean survival under a year.
  • RESULTS: The 18 stereotactic biopsies revealed 14 GBM, 2 grade II astrocytomas, 1 lymphoma, and 1 anaplastic astrocytoma.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Wiley-Liss, Inc.
  • (PMID = 21031506.001).
  • [ISSN] 1522-2586
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / C12A/A1209; United Kingdom / Cancer Research UK / / C8807/A3870
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


92. Mimeault M, Batra SK: Targeting of cancer stem/progenitor cells plus stem cell-based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers. Panminerva Med; 2008 Mar;50(1):3-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting of cancer stem/progenitor cells plus stem cell-based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers.
  • The rapid progression from aggressive primary cancers into locally advanced and invasive and/or metastatic diseases remains a big obstacle for an early diagnosis and curative therapeutic intervention for cancer patients.
  • Of therapeutic interest, the molecular targeting of deregulated signaling elements in cancer stem/progenitor cells and their local microenvironment represents a new potential strategy for the development of more effective clinical treatments against aggressive cancers.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematology Am Soc Hematol Educ Program. 2003;:82-101 [14633778.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] Blood. 2004 Feb 1;103(3):1166-70 [14512297.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2332-6 [14630803.001]
  • [Cites] Cancer Lett. 2004 Feb 20;204(2):213-24 [15013220.001]
  • [Cites] Blood Rev. 2004 Sep;18(3):167-79 [15183901.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(10):1522-9 [15196536.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Jul;51(1):1-28 [15207251.001]
  • [Cites] Nat Immunol. 2004 Jul;5(7):738-43 [15170211.001]
  • [Cites] Transfusion. 2004 Jul;44(7):1087-97 [15225252.001]
  • [Cites] Panminerva Med. 2004 Mar;46(1):49-59 [15238881.001]
  • [Cites] Skin Pharmacol Physiol. 2004 Jul-Aug;17(4):153-66 [15258446.001]
  • [Cites] N Engl J Med. 2004 Aug 12;351(7):657-67 [15306667.001]
  • [Cites] N Engl J Med. 2004 Sep 2;351(10):998-1012 [15342808.001]
  • [Cites] Oncogene. 2004 Sep 20;23(43):7274-82 [15378087.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33 [15381773.001]
  • [Cites] Am J Pathol. 2006 Dec;169(6):2223-35 [17148683.001]
  • [Cites] Expert Opin Biol Ther. 2007 Jan;7(1):41-51 [17150018.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Neurobiol Dis. 2007 Feb;25(2):217-29 [17141509.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1030-7 [17283135.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1113-20 [17283145.001]
  • [Cites] Stem Cells. 2007 Feb;25(2):371-9 [17038675.001]
  • [Cites] J BUON. 2006 Oct-Dec;11(4):433-8 [17309174.001]
  • [Cites] Nature. 2007 Feb 22;445(7130):851-7 [17314971.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2187-96 [17332349.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Mar;20(1):57-65 [17336255.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Feb;5(2):203-15 [17335689.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4635-40 [17299092.001]
  • [Cites] Genes Dev. 2007 Jun 1;21(11):1382-95 [17510286.001]
  • [Cites] Pediatr Blood Cancer. 2007 Aug;49(2):196-8 [17417796.001]
  • [Cites] Mol Vis. 2007;13:823-32 [17615543.001]
  • [Cites] Carcinogenesis. 2007 Jul;28(7):1379-86 [17341655.001]
  • [Cites] Clin Exp Metastasis. 2007;24(5):353-62 [17487557.001]
  • [Cites] Clin Pharmacol Ther. 2007 Sep;82(3):252-64 [17671448.001]
  • [Cites] Stem Cells Dev. 2007 Aug;16(4):637-48 [17784837.001]
  • [Cites] Stem Cells. 2007 Sep;25(9):2302-11 [17569791.001]
  • [Cites] Ann Oncol. 2007 Oct;18(10):1605-19 [17355951.001]
  • [Cites] Carcinogenesis. 2007 Sep;28(9):2053-8 [17434930.001]
  • [Cites] Int J Cancer. 2007 Nov 15;121(10):2125-31 [17565741.001]
  • [Cites] Clin Exp Metastasis. 2007;24(7):485-93 [17653825.001]
  • [Cites] Pigment Cell Res. 2007 Dec;20(6):458-65 [17935489.001]
  • [Cites] Cancer Treat Rev. 2008 May;34(3):247-58 [18226859.001]
  • [Cites] Stem Cell Rev. 2008 Spring;4(1):27-49 [18288619.001]
  • [Cites] Blood. 2000 Feb 1;95(3):1007-13 [10648416.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1166-73 [11493466.001]
  • [Cites] Lancet Oncol. 2002 Jan;3(1):35-43 [11905603.001]
  • [Cites] Nat Immunol. 2002 Jul;3(7):687-94 [12068293.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • [Cites] Cancer Cell. 2002 Sep;2(3):175-8 [12242149.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5657-63 [12384520.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):826-35 [12415253.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7170-4 [12499252.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Pathol Oncol Res. 2003;9(1):13-9 [12704441.001]
  • [Cites] Growth Factors. 2003 Mar;21(1):1-14 [12795332.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):685-94 [12951587.001]
  • [Cites] Cell Mol Life Sci. 2005 Aug;62(16):1863-70 [16003493.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):744-9 [16148886.001]
  • [Cites] Mini Rev Med Chem. 2005 Sep;5(9):805-24 [16178723.001]
  • [Cites] Ernst Schering Found Symp Proc. 2006;(5):155-79 [17939301.001]
  • [Cites] Oncologist. 2007 Oct;12(10):1237-46 [17962617.001]
  • [Cites] Front Biosci. 2008;13:1887-91 [17981676.001]
  • [Cites] J Cell Mol Med. 2007 Sep-Oct;11(5):981-1011 [17979879.001]
  • [Cites] Med Princ Pract. 2008;17(1):84-5 [18059108.001]
  • [Cites] Br J Hosp Med (Lond). 2007 Nov;68(11):589-93 [18087845.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2008 Feb;49(2):636-43 [18235009.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):626-32 [18235122.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Feb;5(2):102-11 [18235442.001]
  • [Cites] Nat Rev Cancer. 2006 Jun;6(6):425-36 [16723989.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1299-308 [16731763.001]
  • [Cites] Eur J Cancer. 2006 Jun;42(9):1309-15 [16682183.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6063-71 [16778178.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2891-6 [16782928.001]
  • [Cites] J Cell Biochem. 2006 Jul 1;98(4):757-69 [16598744.001]
  • [Cites] Hepatology. 2006 Jul;44(1):240-51 [16799977.001]
  • [Cites] Curr Drug Targets. 2006 Jul;7(7):861-79 [16842217.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9 [16849428.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7445-52 [16885340.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1533-8 [16871285.001]
  • [Cites] Cell Cycle. 2006 Aug;5(15):1597-601 [16880743.001]
  • [Cites] Pediatr Blood Cancer. 2006 Oct 15;47(5):560-6 [16395684.001]
  • [Cites] Leuk Lymphoma. 2006 Aug;47(8):1545-52 [16966265.001]
  • [Cites] Mol Cancer Res. 2006 Sep;4(9):607-19 [16966431.001]
  • [Cites] Bone Marrow Transplant. 2006 Oct;38(7):493-9 [16980997.001]
  • [Cites] Hum Mol Genet. 2006 Oct 15;15 Spec No 2:R210-9 [16987886.001]
  • [Cites] Ann Oncol. 2006 Nov;17(11):1620-4 [16600978.001]
  • [Cites] Stem Cells. 2006 Nov;24(11):2319-45 [16794264.001]
  • [Cites] Klin Padiatr. 2006 Nov-Dec;218(6):321-6 [17080334.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):160-9 [17013895.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):16870-5 [17077147.001]
  • [Cites] Panminerva Med. 2006 Sep;48(3):165-74 [17122752.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:219-25 [17124064.001]
  • [Cites] J Cell Mol Med. 2006 Oct-Dec;10(4):857-65 [17125590.001]
  • [Cites] J Cell Mol Med. 2006 Oct-Dec;10(4):995-1013 [17125601.001]
  • [Cites] Clin Invest Med. 2006 Oct;29(5):301-11 [17144440.001]
  • [Cites] Exp Cell Res. 2006 Nov 15;312(19):3701-10 [17046749.001]
  • [Cites] Mol Vis. 2005;11:729-37 [16179903.001]
  • [Cites] Hematology. 2005 Oct;10(5):349-59 [16203604.001]
  • [Cites] Expert Rev Anticancer Ther. 2005 Oct;5(5):835-46 [16221053.001]
  • [Cites] Expert Rev Vaccines. 2005 Oct;4(5):699-710 [16221071.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):323-35 [16226707.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9328-37 [16230395.001]
  • [Cites] Chest. 2005 Oct;128(4):2268-73 [16236883.001]
  • [Cites] Pancreas. 2005 Nov;31(4):301-16 [16258363.001]
  • [Cites] Curr Opin Neurol. 2005 Dec;18(6):639-44 [16280674.001]
  • [Cites] Cancer Lett. 2005 Dec 18;230(2):199-210 [16297706.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2304-12 [16193083.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Haematologica. 2007 Mar;92(3):323-31 [17339181.001]
  • [Cites] PLoS One. 2007;2(3):e293 [17356702.001]
  • [Cites] Br J Haematol. 2007 Apr;137(1):20-35 [17359369.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):967-78 [17363490.001]
  • [Cites] Semin Cancer Biol. 2007 Jun;17(3):241-7 [16839774.001]
  • [Cites] Bone Marrow Transplant. 2007 Apr;39(7):397-400 [17322933.001]
  • [Cites] Cancer Metastasis Rev. 2007 Mar;26(1):203-14 [17273942.001]
  • [Cites] J Thorac Oncol. 2007 Apr;2(4):327-43 [17409807.001]
  • [Cites] Adv Cancer Res. 2007;97:25-60 [17419940.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2007 Mar;115(3):160-5 [17427103.001]
  • [Cites] Oncology. 2006;71(1-2):32-9 [17344669.001]
  • [Cites] Exp Gerontol. 2007 May;42(5):385-90 [17275237.001]
  • [Cites] Curr Eye Res. 2007 Mar;32(3):281-90 [17453948.001]
  • [Cites] Leukemia. 2007 May;21(5):926-35 [17330101.001]
  • [Cites] Nat Rev Drug Discov. 2006 Aug;5(8):649-59 [16883303.001]
  • [Cites] Leukemia. 2007 May;21(5):949-55 [17361218.001]
  • [Cites] Cancer Cell. 2007 May;11(5):421-9 [17482132.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jun;62(3):214-26 [17368038.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2007 Jun 29;362(1482):959-71 [17317642.001]
  • [Cites] Trends Mol Med. 2007 May;13(5):192-9 [17383232.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jun 15;357(4):1084-9 [17466949.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4807-15 [17510410.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4827-33 [17510412.001]
  • [Cites] J Cell Sci. 2007 Feb 1;120(Pt 3):468-77 [17227796.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):707-12 [15361885.001]
  • [Cites] Nature. 1984 Feb 2-8;307(5950):471-3 [6694739.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):165-72 [9440739.001]
  • [Cites] Nat Med. 1998 Sep;4(9):1038-45 [9734397.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):324-31 [15549094.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Springer Semin Immunopathol. 2004 Nov;26(1-2):95-108 [15378271.001]
  • [Cites] Oncogene. 2004 Dec 16;23(58):9392-400 [15558011.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):293-300 [15637392.001]
  • [Cites] Carcinogenesis. 2005 Feb;26(2):495-502 [15513931.001]
  • [Cites] Cell Cycle. 2004 Dec;3(12):1502-5 [15611623.001]
  • [Cites] Nat Rev Cancer. 2005 Feb;5(2):91-101 [15685194.001]
  • [Cites] J Neurooncol. 2005 Jan;71(1):33-8 [15719272.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):275-84 [15803154.001]
  • [Cites] Bone Marrow Transplant. 2005 Apr;35(8):763-6 [15750608.001]
  • [Cites] Med Hypotheses. 2005;64(6):1182-7 [15823713.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3025-9 [15833827.001]
  • [Cites] Am J Clin Oncol. 2005 Jun;28(3):281-8 [15923802.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4490-5 [15930263.001]
  • [Cites] Breast Cancer Res. 2005;7(3):86-95 [15987436.001]
  • [Cites] J Pediatr Surg. 2005 Jun;40(6):936-41; discussion 941 [15991174.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5506-11 [15994920.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6207-19 [16024622.001]
  • [Cites] Neoplasia. 2005 Jun;7(6):623-9 [16036113.001]
  • [Cites] Lancet. 2005 Jul 23-29;366(9482):318-20 [16039336.001]
  • [Cites] Br J Haematol. 2005 Aug;130(3):373-81 [16042686.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):119-30 [16098465.001]
  • [Cites] N Engl J Med. 2005 Aug 25;353(8):811-22 [16120861.001]
  • [Cites] Cancer Cell. 2008 Feb;13(2):153-66 [18242515.001]
  • [Cites] Cell Death Differ. 2008 Mar;15(3):504-14 [18049477.001]
  • [Cites] J Cell Physiol. 2008 May;215(2):287-91 [18205182.001]
  • [Cites] BMC Cancer. 2008;8:48 [18261235.001]
  • [Cites] Growth Factors. 2007 Dec;25(6):400-16 [18365871.001]
  • [Cites] Cell Stem Cell. 2007 Sep 13;1(3):313-23 [18371365.001]
  • [Cites] Endocr Rev. 2008 Apr;29(2):234-52 [18292464.001]
  • [Cites] Clin Pharmacol Ther. 2008 May;83(5):673-91 [17786164.001]
  • [Cites] Breast Cancer Res. 2008;10(1):R10 [18241344.001]
  • [Cites] Semin Oncol. 2005 Dec;32(6 Suppl 9):S78-81 [16399438.001]
  • [Cites] J Invest Dermatol. 2006 Jan;126(1):142-53 [16417230.001]
  • [Cites] J Exp Med. 2006 Jan 23;203(1):73-85 [16380511.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):1022-31 [16108016.001]
  • [Cites] Cancer. 2006 Feb 15;106(4):859-66 [16419074.001]
  • [Cites] Nat Rev Drug Discov. 2006 Feb;5(2):147-59 [16424916.001]
  • [Cites] Cell Cycle. 2006 Feb;5(4):452-6 [16479164.001]
  • [Cites] Oncogene. 2006 Mar 16;25(12):1696-708 [16449977.001]
  • [Cites] J Pediatr Surg. 2006 Apr;41(4):624-32; discussion 624-32 [16567167.001]
  • [Cites] Stem Cells. 2006 Mar;24(3):506-13 [16239320.001]
  • [Cites] J Clin Oncol. 2006 Apr 20;24(12):1924-31 [16567768.001]
  • [Cites] Hum Cell. 2006 Feb;19(1):24-9 [16643604.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4553-7 [16651403.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4532-9 [16469872.001]
  • [Cites] Leuk Lymphoma. 2006 Jan;47(1):1-7 [16321820.001]
  • [Cites] Neoplasia. 2005 Nov;7(11):967-76 [16331882.001]
  • [Cites] Nature. 2005 Dec 8;438(7069):820-7 [16341007.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11459-68 [16357154.001]
  • [Cites] Carcinogenesis. 2006 Jan;27(1):1-22 [16195239.001]
  • [Cites] Nat Rev Neurosci. 2006 Jan;7(1):75-84 [16371952.001]
  • [Cites] Adv Cancer Res. 2007;96:23-50 [17161675.001]
  • [Cites] Mol Cancer. 2006;5:67 [17140455.001]
  • [Cites] Mod Pathol. 2007 Jan;20(1):102-7 [17143262.001]
  • [Cites] Semin Diagn Pathol. 2006 May;23(2):63-9 [17193819.001]
  • [Cites] PLoS Med. 2006 Dec;3(12):e482 [17194186.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] PLoS One. 2006;1:e23 [17183650.001]
  • [Cites] Pediatr Blood Cancer. 2007 Mar;48(3):349-53 [16302216.001]
  • [Cites] Annu Rev Med. 2007;58:267-84 [17002552.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] Expert Opin Biol Ther. 2006 Dec;6(12):1255-62 [17223735.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8 [17210912.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Curr Biol. 2007 Jan 23;17(2):165-72 [17196391.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Feb;13(2):235-44 [17241929.001]
  • [Cites] Neurosurg Clin N Am. 2007 Jan;18(1):59-69, viii-ix [17244554.001]
  • [Cites] Neurosurg Clin N Am. 2007 Jan;18(1):71-80, ix [17244555.001]
  • (PMID = 18427384.001).
  • [ISSN] 0031-0808
  • [Journal-full-title] Panminerva medica
  • [ISO-abbreviation] Panminerva Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA078590; United States / NCI NIH HHS / CA / U01 CA111294; United States / NCI NIH HHS / CA / CA111294; United States / NCI NIH HHS / CA / CA78590
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] Italy
  • [Number-of-references] 210
  • [Other-IDs] NLM/ NIHMS526856; NLM/ PMC3828640
  •  go-up   go-down


93. Salmon JS, Thompson MA, Arildsen RC, Greer JP: Non-Hodgkin's lymphoma involving the liver: clinical and therapeutic considerations. Clin Lymphoma Myeloma; 2006 Jan;6(4):273-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma involving the liver: clinical and therapeutic considerations.
  • Primary hepatic non-Hodgkin's lymphoma (NHL) is a rare disease that presents unique diagnostic and therapeutic challenges.
  • Secondary liver involvement by lymphoma is common and can complicate treatment decisions.
  • A review of the published case reports and the few larger series suggests that primary hepatic NHL represents a heterogeneous mixture of disparate diseases rather than a single entity.
  • There appears to be a strong association between primary hepatic NHL and the hepatitis C virus.
  • Hepatosplenic T-cell lymphoma has attained its own status as a unique disease, whereas case reports suggest that the spectrum of hepatic lymphoma includes many histologies.
  • Involvement of the liver by lymphoma can compound the difficulty of pursuing aggressive chemotherapy in patients who have a life-threatening illness and impaired metabolism of the most effective drugs.
  • [MeSH-major] Liver Neoplasms / therapy. Lymphoma, T-Cell / therapy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16507204.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 92
  •  go-up   go-down


94. Pfreundschuh M, Zwick C, Zeynalova S, Dührsen U, Pflüger KH, Vrieling T, Mesters R, Mergenthaler HG, Einsele H, Bentz M, Lengfelder E, Trümper L, Rübe C, Schmitz N, Loeffler M, German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL): Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol; 2008 Mar;19(3):545-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
  • BACKGROUND: The addition of etoposide to combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone [etoposide to combination chemotherapy with cyclophosphamide, vincristine and prednisone (CHOEP)] improved outcome of young patients with good-prognosis aggressive lymphoma.
  • PATIENTS AND METHODS: Intention-to-treat analysis of 389 young (18-60 years) patients with good-prognosis (age-adjusted International Prognostic Index = 0, 1) aggressive lymphoma randomized to CHOEP-21 (n = 194) or high CHOEP (n = 195).
  • CONCLUSION: Dose-escalated CHOEP-21 does not provide clinical benefit for young patients with good-prognosis aggressive lymphomas.
  • Since differences between chemotherapy regimens are compressed by the addition of rituximab, the results of this trial have bearing on strategies aiming to improve outcome of good-prognosis aggressive lymphomas in the rituximab era.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18065407.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


95. Chanan-Khan A, Holkova B, Goldenberg AS, Pavlick A, Demopoulos R, Takeshita K: Non-Hodgkin's lymphoma presenting as a breast mass in patients with HIV infection: a report of three cases. Leuk Lymphoma; 2005 Aug;46(8):1189-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma presenting as a breast mass in patients with HIV infection: a report of three cases.
  • Breast involvement with non-Hodgkin's lymphoma (NHL) is rare.
  • Patients with AIDS have an increased incidence of NHL, often with high-grade histology, extranodal presentation and aggressive clinical course.
  • Lymphoma of the breast in patients with HIV-1 infection has not been reported.
  • We reviewed our tumor registry database of all AIDS-associated NHL and report on the clinical presentation and long-term outcome of 3 patients with AIDS who presented with lymphomatous involvement of the breast.
  • [MeSH-major] Breast Neoplasms / complications. Breast Neoplasms, Male / complications. HIV Infections / complications. Lymphoma, AIDS-Related / complications. Lymphoma, Non-Hodgkin / complications


96. Vranovsky A, Ladicka M, Lakota J: Autologous stem cell transplantation in first-line treatment of high-risk aggressive non-Hodgkin's lymphoma. Neoplasma; 2008;55(2):107-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplantation in first-line treatment of high-risk aggressive non-Hodgkin's lymphoma.
  • A single center, retrospective analysis evaluating the outcome of patients with poor-risk aggressive non-Hodgkin's lymphoma (NHL) treated with high-dose chemotherapy and autologous stem cell transplantation (ASCT) as a part of firstline therapy.
  • Forty-seven patients younger than 65 years with diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), peripheral T-cell lymphoma (PTCL) or alk-negative anaplastic large cell lymphoma (ALCL) underwent ASCT between July 1997 and November 2005.
  • Our results confirm the efficacy of high-dose therapy with ASCT during first-line treatment of patients with poor-prognosis aggressive lymphoma, with substantial number of patients cured by using this treatment approach.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, Non-Hodgkin / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18652043.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate; DHAP protocol; MACOP-B regimen
  •  go-up   go-down


97. Furman RR, Martin P, Ruan J, Cheung YK, Vose JM, LaCasce AS, Elstrom R, Coleman M, Leonard JP: Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. Cancer; 2010 Dec 1;116(23):5432-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma.
  • A phase 1 evaluation was conducted of bortezomib with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with untreated diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL).
  • [MeSH-major] Antibodies, Monoclonal, Murine-Derived / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Boronic Acids / administration & dosage. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Mantle-Cell / drug therapy. Pyrazines / administration & dosage

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Cancer Society.
  • (PMID = 20665890.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Boronic Acids; 0 / Pyrazines; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 69G8BD63PP / Bortezomib; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


98. Ansell SM, Armitage J: Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc; 2005 Aug;80(8):1087-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin lymphoma: diagnosis and treatment.
  • Non-Hodgkin lymphomas are a heterogeneous group of malignancies of the lymphoid system.
  • B-cell lymphomas account for approximately 90% of all lymphomas, and the 2 most common histological disease entities are follicular lymphoma and diffuse large B-cell lymphoma.
  • Approximately 55,000 to 60,000 new cases of non-Hodgkin lymphoma are diagnosed annually in the United States, a number that has nearly doubled during the past 3 decades.
  • For patients with diffuse large B-cell lymphoma, treatment of limited-stage disease generally includes doxorubicin-based chemotherapy combined with rituximab followed by involved field radiation therapy.
  • Disease relapse is a problem, and high-dose therapy with stem cell support is the treatment of choice for chemosensitive relapsed aggressive lymphomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16092591.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  • [Number-of-references] 74
  •  go-up   go-down


99. Zhai L, Guo C, Cao Y, Xiao J, Fu X, Huang J, Huang H, Guan Z, Lin T: Long-term results of pirarubicin versus doxorubicin in combination chemotherapy for aggressive non-Hodgkin's lymphoma: single center, 15-year experience. Int J Hematol; 2010 Jan;91(1):78-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of pirarubicin versus doxorubicin in combination chemotherapy for aggressive non-Hodgkin's lymphoma: single center, 15-year experience.
  • Few studies have compared the long-term outcomes of patients receiving pirarubicin-based THP-COP and doxorubicin-based CHOP in the treatment of non-Hodgkin's lymphoma (NHL).
  • We retrospectively compared the efficacy and safety of these two regimens in 459 previously untreated aggressive NHL patients admitted to Sun Yat-Sen University Cancer Center from 1987 to 2003.
  • At a median follow-up of 95.7 months, the 8-year survival rates were also similar (overall survival: THP-COP, 55.8% vs. CHOP, 56.7%; progression-free survival: THP-COP, 47.3% vs. CHOP, 43.5%; lymphoma-specific survival: THP-COP, 51.2% vs. CHOP, 48.5%).
  • In combination chemotherapy for aggressive NHL, pirarubicin has comparable efficacy to doxorubicin and has a lower incidence of alopecia, gastrointestinal toxicities, and arrhythmia.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Doxorubicin / analogs & derivatives. Lymphoma, Non-Hodgkin / drug therapy

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cancer Res Clin Oncol. 2004 Feb;130(2):107-13 [14648210.001]
  • [Cites] Int J Mol Med. 1998 Feb;1(2):491-4 [9852255.001]
  • [Cites] Hematol Oncol. 2007 Sep;25(3):107-14 [17457949.001]
  • [Cites] Int J Hematol. 2005 Apr;81(3):246-54 [15814336.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]
  • [Cites] Ann Intern Med. 1979 Nov;91(5):710-7 [496103.001]
  • [Cites] Blood. 2004 Aug 1;104(3):634-41 [15016643.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):579-86 [17242396.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2007 May;29(5):391-5 [17892140.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):602-11 [11157009.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;23(5):311-5 [2706737.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1630-6 [2809679.001]
  • [Cites] Eur J Cancer. 1992;28A(10):1670-6 [1389483.001]
  • [Cites] Gan To Kagaku Ryoho. 1997 Jan;24(1):61-6 [9020947.001]
  • [Cites] J Antibiot (Tokyo). 1979 Oct;32(10):1082-4 [528373.001]
  • [Cites] Leukemia. 1997 Nov;11(11):1817-20 [9369412.001]
  • [Cites] Pediatr Res. 2002 Feb;51(2):256-9 [11809923.001]
  • [Cites] Gan To Kagaku Ryoho. 1984 Jan;11(1):138-42 [6696455.001]
  • [Cites] J Antibiot (Tokyo). 1979 Oct;32(10):1085-6 [528374.001]
  • [Cites] Blood. 2004 Aug 1;104(3):626-33 [14982884.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3121-7 [16754935.001]
  • [Cites] Oncology. 1990;47(1):25-8 [2300381.001]
  • [Cites] Hematol J. 2000;1(1):53-66 [11920170.001]
  • [Cites] Cancer. 1997 Dec 15;80(12):2311-20 [9404709.001]
  • [Cites] Tsitologiia. 1997;39(10):928-37 [9505340.001]
  • [Cites] Rinsho Ketsueki. 1993 Dec;34(12):1532-9 [8295326.001]
  • [Cites] Ann Oncol. 1992 May;3(5):379-86 [1616892.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):847-52 [15465202.001]
  • [Cites] Zhonghua Xue Ye Xue Za Zhi. 2005 Oct;26(10):577-80 [16532963.001]
  • [Cites] Biomed Pharmacother. 1986;40(10):376-9 [3580506.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [